Page last updated: 2024-11-13

oxytetracycline, anhydrous

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Oxytetracycline: A TETRACYCLINE analog isolated from the actinomycete STREPTOMYCES RIMOSUS and used in a wide variety of clinical conditions. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

oxytetracycline : A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID54675779
CHEMBL ID1517
CHEMBL ID1401333
CHEMBL ID461529
CHEMBL ID4280957
CHEBI ID27701
SCHEMBL ID560497
SCHEMBL ID2899
SCHEMBL ID13782651
SCHEMBL ID13169109
MeSH IDM0581119

Synonyms (206)

Synonym
AC-12777
AB01274728-01
KBIO1_000225
DIVK1C_000225
mepatar
oxy-kesso-tetra
stevacin
nsc 9169
berkmycen
oxysteclin
bisolvomycin
nsc-9169
macocyn
oxitetracyclinum
einecs 201-212-8
teravit
dabicycline
geomycin
terramycin im
otc (antibiotic)
liquamycin la 200
oxytetracyclinum [inn-latin]
adamycin
ossitetraciclina [dcit]
ursocycline
solkaciclina
nci-c56473
2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-, (4s-(4alpha,4aalpha,5alpha,5aalpha,6beta,12aalpha))-
brn 2714587
oxytetracid
oxytetracycline (internal use)
oxitetraciclina [inn-spanish]
oxyterracyne
antibiotic tm 25
oxitetracyclin
biostat pa
oxytetracyclin
terrafungine
oksisyklin
fanterrin
tarocyn
geotilin
vendarcin
oxypam
tarosin
tetracycline, 5-hydroxy-
terramycin q50
oxytetracycline [inn]
pennox 200
riomitsin
mycoshield tmqthc 20
biostat
terramitsin
hsdb 3145
ursocyclin
geomycin (streptomyces vimosus)
lenocycline
oxymykoin
tetran
la 200
2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-
proteroxyna
ryomycin
SPECTRUM_001055
PRESTWICK2_000307
oxymycin
2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-, (4s,4ar,5s,5ar,6s,12as)-
tm 5
medamycin
imperacin
15251-48-6
dalimycin
unimycin
oxacycline
(4s,4ar,5s,5ar,6s,12as)-4-(dimethylamino)-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide
IDI1_000225
SPECTRUM5_001148
PRESTWICK3_000307
BSPBIO_002151
BPBIO1_000302
BSPBIO_000274
C06624
79-57-2
oxytetracycline
oxytetracycline anhydrous
hydroxytetracyclinum
oxytetracycline (anhydrous)
5-hydroxytetracycline
embryostat
oxyterracine
DB00595
oxytetracycline amphoteric
oxytetracycline calcium
MLS000069429 ,
smr000059000
KBIO2_001535
KBIO2_004103
KBIO3_001651
KBIOGR_000912
KBIOSS_001535
KBIO2_006671
SPECTRUM2_000988
SPECTRUM3_000536
PRESTWICK1_000307
SPECTRUM4_000466
SPBIO_001055
SPBIO_002493
PRESTWICK0_000307
NINDS_000225
NCGC00091268-04
NCGC00091268-05
(4s,4ar,5s,5ar,6s,12as)-4-(dimethylamino)-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
LMPK07000005
oxytetracycline dehydrate
oxytetracyclinum dihydras
nitox
e703
nsc-757262
terramycine
CHEMBL1517
oxitetracycline
CHEBI:27701 ,
oxytetracyclinum
oxitetraciclina
A839720
NCGC00091268-07
NCGC00091268-06
NCGC00091268-08
NCGC00188956-01
NCGC00091268-09
sr-01000003006
oxytetracycline base
NCGC00255168-01
tox21_302380
cas-79-57-2
dtxcid9014260
dtxsid1034260 ,
AKOS015951277
AKOS015961254
terramicina oftalmica
ossitetraciclina
unii-slf0d9077s
4-14-00-02633 (beilstein handbook reference)
slf0d9077s ,
NCGC00091268-11
doxycycline monohydrate impurity e [ep impurity]
oxytetracycline (anhydrous) [hsdb]
2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-, (4s-(4.alpha.,4a.alpha.,5.alpha.,5a.alpha.,6.beta.,12a.alpha.))-
oxytetracycline [who-dd]
(4s,4ar,5s,5ar,6s,12as)-4-(dimethylamino)-3,5,6,10,12,12ahexahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
doxycycline hyclate impurity e [ep impurity]
oxytetracycline [mi]
doxycycline impurity e
4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
S1773
SCHEMBL560497
HY-B0275
SCHEMBL2899
SCHEMBL13782651
IWVCMVBTMGNXQD-PXOLEDIWSA-N
NCGC00091268-12
SCHEMBL13169109
AC-13466
oxytetracycline (terramycin)
CHEMBL1401333
(4s,4ar,5s,5ar,6s,12ar)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide
OPERA_ID_661
AB00053514_05
AB00053514_04
AB01274728_02
79-57-2 (anhydrous)
mfcd00003700
CHEMBL461529
oxytetra selective supplement, for microbiology
oxytetracycline, european pharmacopoeia (ep) reference standard
SR-01000003006-5
SBI-0051473.P003
galsenomycin
7179-50-2 (calcium (1:1) salt)
5-hydroxy-tetracycline
nsc9169 (hcl)
6153-65-7 (di-hydrochloride salt, di-hydrate)
2058-46-0 (mono-hydrochloride)
6153-64-6 (di-hydrate)
oxytetracycline, british pharmacopoeia (bp) reference standard
oxytetracycline(terramycin)
SW196796-3
bdbm241973
oxytetracycline (dihydrate)
Q411646
E75911
OWFJMIVZYSDULZ-PXOLEDIWSA-N
(4s,4ar,5s,5ar,6s,12as)-4-(dimethylamino)-
1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene
3,5,6,10,12,12a-hexahydroxy-6-methyl-
oxytetracycline,(s)
Q63393012
CCG-269334
gtpl10919
2z,4s,4ar,5s,5ar,6s,12as)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione
CHEMBL4280957
NCGC00091268-10
oxytetracycline 1000 microg/ml in acetonitrile
Z1515385075
terramycin, liquamycin
PD132319

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The three antibiotics were described as belonging to the group of low toxic compounds according to the classification adopted in industrial toxicology."( [Comparative toxicity of oxytetracycline and its semisynthetic derivatives, methacycline and doxycycline].
Anufrieva, RG; Balabanova, EL; Gerasimova, SS; Lapchinskaia, AV; Zel'tser, IZ, 1978
)
0.26
"Human diploid fibroblasts cultured in Dulbecco's Modified Eagle's medium (DME) were exposed to different concentrations of 15 antibiotics to determine the limiting toxic concentration."( Toxicity of antibiotics on cultured human skin fibroblasts.
Byarugaba, W; Koske-Westphal, T; Passarge, E; Rüdiger, HW; Wöhler, W, 1975
)
0.25
" Mycotoxin-detoxifying agents can thus interact with the oral bioavailability of antibiotics depending on the antibiotic and detoxifying agent, with possible adverse effects on the health of animals and humans."( Efficacy and safety testing of mycotoxin-detoxifying agents in broilers following the European Food Safety Authority guidelines.
Croubels, S; De Backer, P; De Baere, S; De Saeger, S; Devreese, M; Eeckhout, M; Goossens, J; Hautekiet, V; Osselaere, A; Vandenbroucke, V; Watteyn, A, 2012
)
0.38
" It was found that OXT and FLO have a stronger adverse effect on duckweed (EC50=3."( Aquatic toxicity of four veterinary drugs commonly applied in fish farming and animal husbandry.
Białk-Bielińska, A; Kołodziejska, M; Kumirska, J; Maszkowska, J; Stepnowski, P; Steudte, S; Stolte, S, 2013
)
0.39
"The objective of our study was the investigation of the toxic properties of two antimicrobial drugs: oxytetracycline (OTC) and trimethoprim (TMP) in the aquatic environment."( The toxic effect of oxytetracycline and trimethoprim in the aquatic environment.
Arnuš, L; Drobne, D; Durjava, MK; Gutmaher, A; Jeretin, B; Kolar, B, 2014
)
0.4
"The study investigated the effect of oxytetracycline (OTC) on the anti-oxidative defense system, the structure (hemolysis rate and morphology) and function (ATP enzyme activity) of human red blood cells (hRBCs) to investigate the possible toxic mechanism of OTC to hRBCs."( Probing the in vitro cytotoxicity of the veterinary drug oxytetracycline.
Chi, Z; Cui, H; Liu, R; Ma, S; You, H; Zhang, Q, 2014
)
0.4
" Indices of soil microbial diversity at 4 mg OTC kg(-1) soil were significantly different from those of the control, indicating the potential adverse effects of OTC to soil microorganisms."( Toxicity of OTC to Ipomoea aquatica Forsk. and to microorganisms in a long-term sewage-irrigated farmland soil.
Chen, L; Christie, P; Luo, Y; Ma, T; Wu, L, 2016
)
0.43
"Although modes of action (MOAs) play a key role in the understanding of the toxic mechanism of chemicals, the MOAs have not been investigated for antibiotics to green algae."( Toxicity of 13 different antibiotics towards freshwater green algae Pseudokirchneriella subcapitata and their modes of action.
Fu, L; Huang, T; Li, C; Su, L; Wang, S; Wang, X; Zhao, Y, 2017
)
0.46
" To evaluate single and combined toxic effects of OTC and Cu on the soil ecology, changes in quantities of bacteria, fungi, and actinomycetes in the soil were studied over a 28-d incubation period by a plate count method, microbes numbers counted on days 7, 14, 21, and 28."( Toxic effects of oxytetracycline and copper, separately or combined, on soil microbial biomasses.
Wang, J; Wang, L; Zhu, L, 2018
)
0.48
"To investigate the adverse effect of two widely used pharmaceuticals, paracetamol (acetaminophen [APAP]) and oxytetracycline (OTC) on the marine rotifer Brachionus rotundiformis (B."( Adverse effects of two pharmaceuticals acetaminophen and oxytetracycline on life cycle parameters, oxidative stress, and defensome system in the marine rotifer Brachionus rotundiformis.
Byeon, E; Han, J; Hwang, UK; Lee, JS; Park, JC; Seo, JS; Yoon, DS, 2018
)
0.48
" However, the combined toxic effects of this phenomenon have yet to be addressed."( Combination of oxytetracycline and quinocetone synergistically induces hepatotoxicity via generation of reactive oxygen species and activation of mitochondrial pathway.
Fan, L; Hou, L; Hu, H; Liu, F; Yin, S; Zhao, C, 2022
)
0.72
"This study aimed to determine the adverse effects of oxytetracycline and enrofloxacin application on the fertility of Saanen bucks."( Adverse effects of oxytetracycline and enrofloxacin on the fertility of Saanen bucks.
Kara, M; Koşal, V; Taşpınar, F; Uslu, BA; Yücel, UM, 2021
)
0.62
" The XGCA model predicts the joint toxicity through molecular structural or nanostructural characters, thus modes of toxic action are not preconditions for predicting the toxicity of the mixtures."( Predicting joint toxicity of chemicals by incorporating a weighted descriptor into a mixture model: Cases for binary antibiotics and binary nanoparticles.
Wang, DG; Wang, Z; Zhang, F, 2022
)
0.72
"Direct discharge of aquaculture wastewater may have toxic effects, due to the presence of heavy metals, antibiotics, and even resistant pathogens, but little attention has been given."( Toxic effects of long-term dual or single exposure to oxytetracycline and arsenic on Xenopus tropicalis living in duck wastewater.
Li, X; Li, Y; Luan, T; Xu, Y; Zhao, J; Zheng, L, 2023
)
0.91
" Thus, such combine pollution should be avoided in safe agricultural product."( Toxicity of emerging contaminant antibiotics in soil to Capsicum annuum L. growth and their effects on it accumulating copper.
Dai, H; Jia, J; Li, R; Skuza, L; Sun, Q; Wei, S; Xue, J, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic variables were then calculated."( Pharmacokinetics of oxytetracycline in presence of calcium gluconate in goats.
Chakraborty, AK; Ghose, RK; Mandal, TK; Sarkar, S, 1992
)
0.28
"In the present study the feed and water consumption and pharmacokinetic parameters of orally administered oxytetracycline were compared in clinically healthy pigs and in the same pigs following a challenge with Actinobacillus (Haemophilus) pleuropneumoniae toxins."( The influence of disease on feed and water consumption and on pharmacokinetics of orally administered oxytetracycline in pigs.
Pijpers, A; Schoevers, EJ; van Gogh, H; van Leengoed, LA; van Miert, AS; Verheijden, JH; Visser, IJ, 1991
)
0.28
" There was no difference in the pharmacokinetic profile of OTC following administration of 50 mg/kg compared to 10 mg/kg."( The pharmacokinetics of oxytetracycline following intravenous administration in healthy and diseased pigs.
Pijpers, A; Schoevers, EJ; van Gogh, H; van Leengoed, LA; van Miert, AS; Verheijden, JH; Visser, IJ, 1990
)
0.28
" Significant reductions were observed over RF class in OTC pharmacokinetic parameters for elimination and distribution but not for oral absorption."( An experimental model for pharmacokinetic analysis in renal failure.
Bevill, RF; Duffee, NE; Koritz, GD; Schaeffer, DJ, 1990
)
0.28
" Plasma OTC concentration decreased slowly for 168 hours (elimination phase) after drug administration, and the elimination half-life was 23."( Oxytetracycline pharmacokinetics, tissue depletion, and toxicity after administration of a long-acting preparation at double the label dosage.
TerHune, TN; Upson, DW, 1989
)
0.28
" The drug had a rapid distribution phase followed by a relatively slow elimination phase, with half-life of 16 hours."( Bioavailability, pharmacokinetics, and plasma concentration of tetracycline hydrochloride fed to swine.
Bane, DP; Bevill, RF; Hall, WF; Kniffen, TS; Koritz, GD, 1989
)
0.28
"Oxytetracycline (OTC) pharmacokinetic values in plasma and bile were ascertained after IV administration of the drug."( Pharmacokinetics of oxytetracycline in the turkey: evaluation of biliary and urinary excretion.
Dyer, DC, 1989
)
0.28
"A comparative pharmacokinetic study was conducted in rainbow trout (Salmo gairdneri) and African catfish (Clarias gariepinus) following intravenous (i."( Comparative pharmacokinetics of oxytetracycline in rainbow trout (Salmo gairdneri) and African catfish (Clarias gariepinus).
Driessens, F; Grondel, JL; Nouws, JF; Schutte, AR, 1989
)
0.28
" The half-life of the elimination phase was calculated to be 11."( Pharmacokinetics of oxytetracycline in clinical cases in the red-necked wallaby (Macropus rufogriseus).
Gulland, FM; Kirkwood, JK; Needham, JR; Vogler, MG, 1988
)
0.27
" Although the elimination half-life of gentamicin appeared to decrease with age, the changes were not significant and were due to an increased elimination rate in only one calf."( Comparative pharmacokinetics of gentamicin, neomycin and oxytetracycline in newborn calves.
Barto, PB; Burrows, GE; Martin, B, 1987
)
0.27
" For obtaining pharmacokinetic reference parameters, one 10% OTC formulation was administered intravenously."( Comparative pharmacokinetics, bioavailability and renal clearance of five parenteral oxytetracycline-20% formulations in dairy cows.
Breukink, HJ; Driessens, F; Mevius, DJ; Nouws, JF; Verkaik, R; Vree, TB, 1986
)
0.27
" Decreased concentrations of oxytetracycline, area under the curve, peak concentration and rate constant for elimination were observed in patients with type IV."( Comparative pharmacokinetics of doxycycline and oxytetracycline in patients with hyperlipidemia.
Gawrońska-Szklarz, B; Kalinowski, W; Wójcicki, J, 1985
)
0.27
"Following intravenous administration of an oxytetracycline-HC1 and an oxytetracycline-dihydrate formulation to dairy cows, no statistical difference could be found between the pharmacokinetic parameters, derived from the three-compartment model, of these preparations."( Pharmacokinetics and renal clearance of oxytetracycline after intravenous and intramuscular administration to dairy cows.
Binkhorst, GJ; Breukink, HJ; Lohuis, J; Nouws, JF; Termond, E; van Lith, P; Vree, TB, 1985
)
0.27
" Two of these formulations were injected intravenously to obtain reference values of the drug's pharmacokinetic parameters."( Comparative pharmacokinetics and bioavailability of eight parenteral oxytetracycline-10% formulations in dairy cows.
Binkhorst, GJ; Breukink, HJ; Lohuis, J; Mevius, DJ; Nouws, JF; van Lith, P; Vree, TB, 1985
)
0.27
" Pharmacokinetic parameters, including serum half-life (t1/2) and apparent volume of distribution (Vd) were calculated from the OTC concentration-time curves for each species and route of administration."( Pharmacokinetics of a long-acting oxytetracycline preparation in ring-necked pheasants, great horned owls, and Amazon parrots.
Graham, DL; Schwark, WS; Shin, SJ; Teare, JA, 1985
)
0.27
" The half-life (t1/2) after IV administration varied between 169."( Pharmacokinetics and plasma protein binding (in vitro) of oxytetracycline in buffalo (Bubalus bubalis).
Paul, BS; Varma, KJ, 1983
)
0.27
"The pharmacokinetic properties and local tolerance of three oxytetracycline formulations, one conventional (Engemycine, 10%) and two long-acting (Oxyter LA, 20% and Terramycin LA, 20%) were compared in clinically healthy cross-bred pigs following intramuscular injection of single doses (20 mg/kg body weight) in the neck region."( Comparison of the pharmacokinetics and local tolerance of three injectable oxytetracycline formulations in pigs.
Baggot, JD; Banting, AL, 1996
)
0.29
"The aim of this study was to assess the differences in the values of the pharmacokinetic parameters attributable to the use of either linear or nonlinear regression analysis and to find the effect of weighting schemes on these differences."( The effects of the method of calculation on the evaluation of the pharmacokinetic parameters of oxytetracycline after intravenous administration to calves.
Errecalde, JO; Mariño, EL; Mestorino, N, 1997
)
0.3
" The pharmacokinetic parameters were described by a two-compartment open model."( Comparative pharmacokinetics of ampicillin trihydrate, gentamicin sulphate and oxytetracycline hydrochloride in Nubian goats and desert sheep.
Ali, BH; Elsheikh, HA; Osman, IA, 1997
)
0.3
" No statistically significant changes were observed in the pharmacokinetic parameters describing the distribution of the drug at this dehydration level."( Effect of dehydration on the pharmacokinetics of oxytetracycline hydrochloride administered intravenously in goats (Capra hircus).
Elsheikh, HA; Eltayeb, IB; Osman Intisar, AM; Salam Abdullah, A, 1998
)
0.3
" The elimination half-life (t1/2 beta) and the apparent volume of distribution [vd(area)] were slightly increased in febrile calves, as compared to healthy animals."( Influence of Escherichia coli endotoxin induced fever on the pharmacokinetics and dosage regimen of oxytetracycline in cross-bred calves.
Nauriyal, DC; Sharma, SK; Singh, RP; Srivastava, AK, 1998
)
0.3
" administration, the elimination half-life (t1/2) was 62."( Pharmacokinetics of oxytetracycline in the red pacu (Colossoma brachypomum) following different routes of administration.
Doi, AM; Lewbart, GA; Stoskopf, MK, 1998
)
0.3
"The pharmacokinetic behaviour of oxytetracycline (OTC) was studied in 11 sheep after intravenous and intramuscular administration at a single dosage of 20 mg kg(-1) bodyweight."( Pharmacokinetics of oxytetracycline after intramuscular administration with lidocaine in sheep, comparison with a conventional formulation.
Carceles, CM; Guimerá, ME; Moreno, L; Serrano, JM,
)
0.13
" Samples were analysed by a high-performance liquid chromatography method and the pharmacokinetic parameters were processed using the minimum Akaike information criterion estimation (MAICE) test."( Pharmacokinetics and residual behaviour in milk of oxytetracycline in cows following administration of uterine pessaries.
Ermini, L; Roncada, P; Schleuning, A; Stracciari, GL; Strocchia, A, 2000
)
0.31
"The pharmacokinetic properties of oxytetracycline were studied following a single injection of a long-acting formulation (20 mg/kg body weight) into the semimembranosus muscle of healthy dogs and of dogs that had been experimentally infected with Ehrlichia canis."( The pharmacokinetics of a long-acting oxytetracycline formulation in healthy dogs and in dogs infected with Ehrlichia canis.
Buoro, IB; Kikuvi, GM; Mitema, ES, 2001
)
0.31
"To determine for two commercial preparations of oxytetracycline (OTC) the pharmacokinetic behaviour, the presence of detectable milk residues and the penetration in milk of OTC administered by intravenous (IV) (conventional formulation [CF]) and intramuscular (IM) routes (CF and long-acting [LA] formulations) in goats producing milk."( Pharmacokinetics and residues in milk of oxytetracyclines administered parenterally to dairy goats.
Garcia, J; Moreno, L; Moyano, R; Roman, AG; Rule, R; Serrano, JM, 2001
)
0.31
" The plasma pharmacokinetic parameters were calculated using a two-compartment model."( Pharmacokinetics and residues in milk of oxytetracyclines administered parenterally to dairy goats.
Garcia, J; Moreno, L; Moyano, R; Roman, AG; Rule, R; Serrano, JM, 2001
)
0.31
" Muscle lesions were quantitatively evaluated by ultrasonography and by use of pharmacokinetic analysis of plasma creatine kinase activity, and both were compared with a comprehensive planimetric computer-assisted analysis of the injection sites after euthanasia."( Comparison of ultrasonography and pharmacokinetic analysis of creatine kinase release for quantitative assessment of postinjection muscle damage in sheep.
Chanoit, GP; Concordet, D; Ferré, JP; Ferré, PJ; Laroute, V; Lefebvre, HP; Manesse, M, 2001
)
0.31
" Quantitative evaluation of muscle damage by use of pharmacokinetic analysis of creatine kinase (12."( Comparison of ultrasonography and pharmacokinetic analysis of creatine kinase release for quantitative assessment of postinjection muscle damage in sheep.
Chanoit, GP; Concordet, D; Ferré, JP; Ferré, PJ; Laroute, V; Lefebvre, HP; Manesse, M, 2001
)
0.31
" Pharmacokinetic analysis of creatine kinase provides an accurate quantitative evaluation of macroscopic muscle damage after IM administration of drugs."( Comparison of ultrasonography and pharmacokinetic analysis of creatine kinase release for quantitative assessment of postinjection muscle damage in sheep.
Chanoit, GP; Concordet, D; Ferré, JP; Ferré, PJ; Laroute, V; Lefebvre, HP; Manesse, M, 2001
)
0.31
" Drug disposition data can be scaled across species when chronological time is substituted by the appropriate measure of pharmacokinetic time."( Mixed-effects modeling of the interspecies pharmacokinetic scaling of oxytetracycline.
Martín-Jiménez, T; Riviere, JE, 2002
)
0.31
" The serum pharmacokinetic parameters of OTC in goats were determined, with a mean AUC=67."( Serum pharmacokinetics and tissue and milk residues of oxytetracycline in goats following a single intramuscular injection of a long-acting preparation and milk residues following a single subcutaneous injection.
Babish, JG; Bulgin, M; Craigmill, AL; Lane, M; Payne, MA; Wetzlich, S, 2002
)
0.31
"A physiologically based pharmacokinetic model (PBPK) for oxytetracycline (OTC) residues in sheep was developed using previously published data from a combined serum pharmacokinetic and tissue residue study [Craigmill et al."( A physiologically based pharmacokinetic model for oxytetracycline residues in sheep.
Craigmill, AL, 2003
)
0.32
"Investigators frequently face the quandary of how to interpret the often times disparate pharmacokinetic parameter values reported in the literature."( Meta-analysis of pharmacokinetic data of veterinary drugs using the Food Animal Residue Avoidance Databank: oxytetracycline and procaine penicillin G.
Craigmill, AL; Gehring, R; Miller, GR; Pierce, AN; Riviere, JE, 2004
)
0.32
"09 L/kg, with a harmonic mean elimination half-life of 15."( Pharmacokinetic disposition of a long-acting oxytetracycline formulation after single-dose intravenous and intramuscular administrations in the American alligator (Alligator mississippiensis).
Bennett, RA; Helmick, KE; Jacobson, ER; Papich, MG; Vliet, KA, 2004
)
0.32
" route, means for systemic availability, maximum plasma concentration, and elimination half-life were 91."( Pharmacokinetics of oxytetracycline in loggerhead sea turtles (Caretta caretta) after single intravenous and intramuscular injections.
Harms, CA; Hohn, AA; Papich, MG; Rodriguez, MX; Ross, PM; Stamper, MA, 2004
)
0.32
"The pharmacokinetic profile of orally administered oxytetracycline (10 mg/kg body weight) was studied 7 days post oral treatment of Piper longum (15 mg equivalent/kg) in White Leghorn hens (2-2."( Alteration of pharmacokinetics of oxytetracycline following oral administration of Piper longum in hens.
Singh, M; Srivastava, AK; Telang, RS; Varshneya, C, 2005
)
0.33
"The purpose of this study was to determine whether Japanese quail (Coturnix japonica) would serve as a pharmacokinetic animal model for two small companion parrots: cockatiels (Nymphicus hollandicus) and Poicephalus parrots."( Investigation of Japanese quail (Coturnix japonica) as a pharmacokinetic model for cockatiels (Nymphicus hollandicus) and Poicephalus parrots via comparison of the pharmacokinetics of a single intravenous injection of oxytetracycline hydrochloride.
Craigmill, AL; Kass, PH; Nugent-Deal, J; Osofsky, A; Tell, LA; Wetzlich, SE, 2005
)
0.33
" The aim of this study was to detail complete pharmacokinetic information of OTC in the Pacific white shrimp."( The complete analysis of oxytetracycline pharmacokinetics in farmed Pacific white shrimp (Litopenaeus vannamei).
Chandumpai, A; Chiayvareesajja, S; Faroongsarng, D; Theapparat, Y, 2006
)
0.33
"3 h, Cmax = 55."( Pharmacokinetics of oxytetracycline in the American horseshoe crab, Limulus polyphemus.
Jones, D; Nolan, MW; Smith, SA, 2007
)
0.34
"48 microg/ml and a prolonged elimination half-life (T1/2beta: 47."( Pharmacokinetics and tissue residues of an oxytetracycline/diclofenac combination in cattle.
Errecalde, JO; Marchetti, L; Mariño Hernández, E; Mestorino, N, 2007
)
0.34
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The elimination half-life of the terminal part of the elimination phase (t(1/2β) ) ranged from 87."( Pharmacokinetics of oxytetracycline in hemolymph from the Chinese mitten crab, Eriocheir sinensis.
Feng, Q; Gu, W; Ji, HY; Jiang, XJ; Liang, TM; Wang, W; Wu, GH, 2011
)
0.37
" Pharmacokinetic parameters were comparable to those reported for eutherians of equivalent size and suggest that the practice of adjusting allometrically scaled doses to account for the lower metabolic rate of marsupials may not be valid."( Single-dose pharmacokinetics of oxytetracycline and penicillin G in tammar wallabies (Macropus eugenii).
Barker, IK; Crawshaw, G; Hinds, LA; Johnson, R; McLelland, DJ; Spilsbury, L, 2011
)
0.37
"Mixed populations of plasmid donor (Salmonella Typhimurium) and recipient (E coli) bacteria were assigned to 1 of 2 simulated oxytetracycline dosing regimens (high peak concentration-short elimination half-life [HC-SHL] or low peak concentration-long elimination half-life [LC-LHL]) or served as untreated control replicates."( Effects of two simulated oxytetracycline dosing regimens on horizontal transfer of antimicrobial resistance plasmids in an in vitro pharmacodynamic model.
Apley, MD; Coetzee, JF; Havel, JA; Lubbers, BV; Narayanan, SK; Peterson, GJ, 2011
)
0.37
" The elimination half-life was estimated as 85."( Oxytetracycline pharmacokinetics in rainbow trout during and after an orally administered medicated feed regimen.
Kane, AS; Miller, RA; Pelsor, FR; Reimschuessel, R, 2012
)
0.38
" However, using in vitro susceptibility in CAMHB and in vivo-determined pharmacokinetic (PK) variables, average and minimum oxytetracycline concentrations relative to MIC (C(av)/MIC and C(min)/MIC) predicted achievement of efficacy for approximately 48 hours after dosing."( Pharmacodynamics of oxytetracycline administered alone and in combination with carprofen in calves.
Brentnall, C; Cheng, Z; Lees, P; McKellar, QA, 2012
)
0.38
"A tissue cage model of inflammation in calves was used to determine the pharmacokinetic and pharmacodynamic properties of individual carprofen enantiomers, following the administration of the racemate."( Influence of oxytetracycline on carprofen pharmacodynamics and pharmacokinetics in calves.
Brentnall, C; Cheng, Z; Lees, P; McKellar, QA, 2013
)
0.39
"The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of oxytetracycline were investigated, when administered both alone and in the presence of carprofen, in healthy calves."( Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline administered alone and in combination with carprofen in calves.
Brentnall, C; Cheng, Z; Lees, P; McKellar, QA, 2013
)
0.39
" To establish a quantitative model for predicting OTC plasma and tissue exposure, a permeability-limited multiroute physiologically based pharmacokinetic model was developed in dogs."( Development and application of a multiroute physiologically based pharmacokinetic model for oxytetracycline in dogs and humans.
Gehring, R; Li, M; Lin, Z; Riviere, JE, 2015
)
0.42
" Plasma concentrations of OTC were determined using liquid chromatography-tandem mass spectrometry and non-compartmental pharmacokinetic analysis was then conducted."( Pharmacokinetics of oxytetracycline in broiler chickens following different routes of administration.
Barski, D; Grabowski, T; Jaroszewski, JJ; Jasiecka, A; Ziółkowski, H; Zuśka-Prot, M, 2016
)
0.43
" Plasma concentrations of oxytetracycline were determined by competitive enzyme-linked immunoabsorbent assay, and pharmacokinetic parameters were obtained."( Pharmacokinetics of Short- and Long-acting Formulations of Oxytetracycline After Intramuscular Administration in Chickens.
Gberindyer, AF; Okpeh, ER; Semaka, AA, 2015
)
0.42
" OTC concentrations in plasma were determined using liquid chromatography-tandem mass spectrometry, after which non-compartmental pharmacokinetic analysis was conducted."( Metal ion-oxytetracycline pharmacokinetic interactions after oral co-administration in broiler chickens.
Grabowski, T; Jaroszewski, JJ; Jasiecka, A; Przybysz, J; Ziółkowski, H; Zuśka-Prot, M, 2016
)
0.43
"Many physiologically based pharmacokinetic (PBPK) models for environmental chemicals, drugs, and nanomaterials have been developed to aid risk and safety assessments using acslX."( Performance Assessment and Translation of Physiologically Based Pharmacokinetic Models From acslX to Berkeley Madonna, MATLAB, and R Language: Oxytetracycline and Gold Nanoparticles As Case Examples.
Fisher, JW; He, C; Jaberi-Douraki, M; Jin, S; Lin, Z; Riviere, JE; Yang, RSH, 2017
)
0.46
" The pharmacokinetic studies were performed on DAC-OTC composite system and commercial tablet (COTA)."( Potential of di-aldehyde cellulose for sustained release of oxytetracycline: A pharmacokinetic study.
Chanda, D; Khare, P; Mishra, D; Shanker, K; Singh, A, 2019
)
0.51
" This study focuses on developing a physiologically based pharmacokinetic (PBPK) model for OTC in sheep and goats."( Development and Application of an Interactive Physiologically Based Pharmacokinetic (iPBPK) Model to Predict Oxytetracycline Tissue Distribution and Withdrawal Intervals in Market-Age Sheep and Goats.
Baynes, RE; Davis, JL; Lin, Z; Maunsell, FP; Riad, MH; Riviere, JE; Tell, LA, 2021
)
0.62
" Furthermore, the pharmacokinetic parameters of oral route were also compared with parenteral route."( Pharmacokinetics, bioavailability and withdrawal period of antibiotic oxytetracycline in catfish Pangasianodon hypophthalmus.
Baitha, R; Bera, AK; Das, BK; Das, N; Krishna, N; Kumar, A; Manna, SK; Nag, SK; Patil, PK; Ravindran, R; Sarkar, DJ, 2022
)
0.72
" The objective of this study was to develop a physiologically based pharmacokinetic (PBPK) model describing the passage of drugs into the milk of lactating species."( A physiologically based pharmacokinetic (PBPK) model exploring the blood-milk barrier in lactating species - A case study with oxytetracycline administered to dairy cows and goats.
Chotard-Soutif, MP; Couet, W; Gehring, R; Grégoire, N; Jacobs, M; Laurentie, M; LeRoux-Pullen, L; Magnier, R; Marchand, S; Mirfendereski, H; Paraud, C; Tardiveau, J; Touchais, G; Viel, A, 2022
)
0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
"Six treatment regimens using oxytetracycline (OTC) combined with streptomycin (ST) were evaluated for eliminating Brucella melitensis from 480 naturally-infected sheep and goats."( Treatment of Brucella melitensis infection in sheep and goats with oxytetracycline combined with streptomycin.
Bekairi, SI; Mukayel, AA; Radwan, AI, 1992
)
0.28
"Twenty-four rams inoculated with Brucella ovis by conjunctival and preputial routes were treated with a long-acting oxytetracycline alone or in combination with dihydrostreptomycin sulfate."( Efficacy of long-acting oxytetracycline alone or in combination with streptomycin for treatment of Brucella ovis infection of rams.
Barberán, M; Blasco, JM; Jiménez de Bagués, MP; Marín, CM, 1989
)
0.28
"The efficacy of oxytetracycline (OTC) alone or combined with streptomycin in the treatment of 118 Najdi ewes believed to have been naturally infected with Brucella melitensis, was evaluated by culture of selected tissues and organs at slaughter."( Experimental treatment of Brucella melitensis infection in sheep with oxytetracycline alone or combined with streptomycin.
al-Aska, AK; al-Jalaifi, M; al-Mukayel, AA; al-Yamani, MJ; Bekairi, SI; Hafez, SM; Radwan, AI, 1989
)
0.28
"Twenty-nine Brucella abortus culture-positive cows were treated with a long-acting oxytetracycline (20 mg/kg of body weight, IM) alone or combined with streptomycin (25 mg/kg, IM or IV) or were re-treated with the same product."( Efficacy of long-acting oxytetracycline alone or combined with streptomycin in the treatment of bovine brucellosis.
Altvater, L; Hoffmann, E; Milward, FW; Nicoletti, P, 1985
)
0.27
"To test eradication and adverse events of ranitidine bismuth citrate (RBC) when given with metronidazole and either oxytetracycline or spiramycin."( Spiramycin is comparable to oxytetracycline in eradicating H. pylori when given with ranitidine bismuth citrate and metronidazole.
Bang, CJ; Berstad, A; Coll, P; Hatlebakk, JG; Hausken, T; Nysaeter, G; Olafsson, S; Olafsson, T; Tefera, S, 1999
)
0.3
"The aim of this paper was to compare the effect of flumethasone and meloxicam in combination with oxytetracycline on clinical and immunological parameters of calves suffering from enzootic bronchopneumonia."( Effect of steroidal and non-steroidal anti-inflammatory drugs in combination with long-acting oxytetracycline on non-specific immunity of calves suffering from enzootic bronchopneumonia.
Bednarek, D; Kandefer-Szerszeń, M; Kondracki, M; Zdzisińska, B, 2003
)
0.32
" Combined with cell-sheet technology, a novel small compound was applied to the treatment of full-thickness knee cartilage defects in murine and canine models."( [Novel small compound in combination with cell-sheet technology for articular cartilage regeneration].
Chung, Ui; Hojo, H; Yano, F, 2011
)
0.37
" There were no clinically relevant differences in the PK profile of oxytetracycline when administered alone and when administered with carprofen."( Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline administered alone and in combination with carprofen in calves.
Brentnall, C; Cheng, Z; Lees, P; McKellar, QA, 2013
)
0.39
"This study investigated the synergistic effects of oxolinic acid (OA) combined with oxytetracycline (OTC) on white shrimp (Penaeus vannamei)."( Synergistic effects of dietary oxolinic acid combined with oxytetracycline on nonspecific immune responses and resistance against Vibrio parahaemolyticus infection of white shrimp (Penaeus vannamei).
Chang, JJ; Chen, BY; Chen, YY; Huang, HT; Lin, YR; Nan, FH; Wu Chang, YH, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
" 3 The mean bioavailability of oxytetracycline was greatest with preparations of the hydrochloride, and with film-coated tablets of the dihydrate."( Bioavailability and dissolution of different formulations of oxytetracycline preparations.
Barber, HE; Calvey, TN; Hart, A, 1975
)
0.25
"Differences in bioavailability of many drugs from their various dosage forms have been shown to be relatively common in human medicine."( Bioavailability and bioinequivalence of drug formulations in small animals.
Watson, AD, 1992
)
0.28
" The pharmacokinetics and bioavailability of oxolinic acid and oxytetracycline were studied in rainbow trout at a water temperature of 16 degrees C after intravascular (10 and 20 mg/kg, respectively) and oral (75 mg/kg) dosing."( Comparative pharmacokinetics and bioavailability of oxolinic acid and oxytetracycline in rainbow trout (Oncorhynchus mykiss).
Björklund, HV; Bylund, G, 1991
)
0.28
"Effect of chronic administration of aspirin, phenobarbitone and oxytetracycline under therapeutic doses on the bioavailability of vitamin A was determined in different groups of albino rats."( Effect of chronic administration of aspirin, phenobarbitone and oxytetracycline on the plasma levels of vitamin A in albino rats.
Hashmi, AS; Maqbool, T; Shah, BH, 1990
)
0.28
"The bioavailability of orally given oxytetracycline in dependence on calcium (0."( [Effect of citric acid and calcium on the bioavailability of orally-administered oxytetracycline in piglets].
Nietlispach, G; Sutter, HM; Wanner, M, 1990
)
0.28
" Some practical advice to improve the bioavailability of OTC is given."( [Oxytetracycline and oral herd treatment: a literature review].
Jager, LP; Prenen, GH; Schaftenaar, W; Seinhorst, JW, 1990
)
0.28
" The bioavailability for both groups was similar; 19."( Chlortetracycline in swine--bioavailability and pharmacokinetics in fasted and fed pigs.
Bane, DP; Bevill, RF; Hall, WF; Kilroy, CR; Koritz, GD, 1990
)
0.28
"A 2 X 2 crossover design trial was conducted in gilts to determine the bioavailability and pharmacokinetics of tetracycline hydrochloride."( Bioavailability, pharmacokinetics, and plasma concentration of tetracycline hydrochloride fed to swine.
Bane, DP; Bevill, RF; Hall, WF; Kniffen, TS; Koritz, GD, 1989
)
0.28
" Bioavailability of OTC was 47."( Pharmacokinetics of oxytetracycline in the turkey: evaluation of biliary and urinary excretion.
Dyer, DC, 1989
)
0.28
" Comparatively, the long-acting oxytetracycline had a smaller rate constant for disposition, a larger volume of distribution divided by bioavailability constant, and a longer half-life."( Oxytetracycline concentrations in plasma and lung of healthy and pneumonic calves, using two oxytetracycline preparations.
Ames, TR; Patterson, EB, 1985
)
0.27
"A series of studies was previously devoted to the dependence of the bioavailability of various tetracyclines on their coordination with calcium and magnesium ions."( Metal ion-tetracycline interactions in biological fluids. Part 5. Formation of zinc complexes with tetracycline and some of its derivatives and assessment of their biological significance.
Berthon, G; Brion, M; Lambs, L, 1985
)
0.27
" Computer simulations run on this occasion showed that the stoichiometry of these species do actually condition the bioavailability of the antibiotics in blood plasma during treatment, the fraction of free base being quite negligible with regard to the metal-bound one."( Metal ion-tetracycline interactions in biological fluids. Part 3. Formation of mixed-metal ternary complexes of tetracycline, oxytetracycline, doxycycline and minocycline with calcium and magnesium, and their involvement in the bioavailability of these an
Berthon, G; Brion, M; Lambs, L, 1984
)
0.27
" The results were used, together with those previously obtained on the complexation of these tetracyclines with proton and calcium, to assess the influence of the two alkali earth metal ions on the bioavailability of these drugs in blood plasma."( Metal ion-tetracycline interactions in biological fluids. 2. Potentiometric study of magnesium complexes with tetracycline, oxytetracycline, doxycycline, and minocycline, and discussion of their possible influence on the bioavailability of these antibioti
Berthon, G; Brion, M; Lambs, L, 1983
)
0.27
"The bioavailability of oxytetracycline (OTC) and chlortetracycline (CTC) was studied in non-fasting calves."( The availability of tetracyclines in calves.
Jacobsson, SO; Luthman, J,
)
0.13
" For different points in time after injection the partial bioavailability was calculated."( Effect of injection site on the bioavailability of an oxytetracycline formulation in ruminant calves.
Nouws, JF; Vree, TB, 1983
)
0.27
" Its dissolution rate constant was 3 times as higher which makes this crystalline modification of oxytetracycline hydrochloride preferable for preparation of the antibiotic pharmaceutical forms with high bioavailability levels."( [Effect of crystallinity on the rate of solution of oxytetracycline hydrochloride].
Grakovskaia, LK; Nesterova, LIa, 1982
)
0.26
" 50 mg/kg given orally with a milk replacer were found to have a mean bioavailability of 46."( Pharmacokinetics of oxytetracycline and therapeutic implications in veal calves.
Galeazzi, RL; Nicolet, J; Schifferli, D; Wanner, M, 1982
)
0.26
" Therefore, formulation of specific diets to administer drugs to farmed fish could assure better bioavailability of the chemotherapeutant and shorter withdrawal times."( Effect of temperature and diet composition on residue depletion of oxytetracycline in cultured channel catfish.
Luzzana, U; Maggi, GL; Moretti, VM; Polidori, P; Serrini, G; Valfrè, F, 1994
)
0.29
"Two new bioavailability parameters were recently suggested [Koeleman et al."( The application of new bioavailability parameters in the bioequivalence testing of antimicrobial agents.
Ellis, SM; Koeleman, HA; Steyn, HS; Wessels, JC, 1993
)
0.29
" The bioavailability was in general low for all the three tetracyclines."( Bioavailability of oxytetracycline, tetracycline and chlortetracycline after oral administration to fed and fasted pigs.
Gyrd-Hansen, N; Nielsen, P, 1996
)
0.29
"25 h and the bioavailability was 49."( Pharmacokinetics of oxytetracycline in the red pacu (Colossoma brachypomum) following different routes of administration.
Doi, AM; Lewbart, GA; Stoskopf, MK, 1998
)
0.3
" In both cases, a biphasic absorption, a 'flip-flop' model and a complete bioavailability were found."( Pharmacokinetics of oxytetracycline after intramuscular administration with lidocaine in sheep, comparison with a conventional formulation.
Carceles, CM; Guimerá, ME; Moreno, L; Serrano, JM,
)
0.13
" The intramuscular bioavailability of the drug was 89."( Some pharmacokinetic parameters and dosage regimens for a long-acting formulation of oxytetracycline in 6- to 8-month-old male calves.
Kumar, R; Malik, JK, 1998
)
0.3
" Finally, the bioavailability of OTC CF = 92."( Pharmacokinetics and residues in milk of oxytetracyclines administered parenterally to dairy goats.
Garcia, J; Moreno, L; Moyano, R; Roman, AG; Rule, R; Serrano, JM, 2001
)
0.31
"Plasma concentration-time values of OTC administered parenterally in production dairy goats showed similar bioavailability for the two pharmaceutical preaprations."( Pharmacokinetics and residues in milk of oxytetracyclines administered parenterally to dairy goats.
Garcia, J; Moreno, L; Moyano, R; Roman, AG; Rule, R; Serrano, JM, 2001
)
0.31
" The relative bioavailability and C(max) of test product to those of reference product was 65."( Lack of bioequivalence of two oxytetracycline formulations in the rabbit.
Chong, W; Han, SK; Kim, SD; Kim, YJ; Ryu, PD, 2002
)
0.31
" Oxolinic acid was found to be well absorbed by gilthead sea bream (92%) and sharpsnout sea bream (88%) while the absorption of OTC was found to be considerably lower in both species (27 and 40%, respectively)."( Potential drug (oxytetracycline and oxolinic acid) pollution from Mediterranean sparid fish farms.
Alexis, M; Nengas, I; Rigos, G; Troisi, GM, 2004
)
0.32
" These efflux transporters excrete their substrates, among other various classes of antibiotics, into the lumen thus reducing net absorption as indicated by a low bioavailability after oral administration."( P-glycoprotein-mediated transport of oxytetracycline in the Caco-2 cell model.
Fink-Gremmels, J; Schrickx, J, 2007
)
0.34
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
" The relative bioavailability was 82."( Muscle tissue kinetics of oxytetracycline following intramuscular and oral administration at two dosages to giant freshwater shrimp (Macrobrachium rosenbergii).
Imsilp, K; Jermnak, U; Kumagai, S; Poapolathep, A; Poapolathep, S; Sugita-Konishi, Y; Wannapat, N, 2008
)
0.35
"High adsorption capacity of carbon nanotubes (CNTs) may greatly determine the bioavailability and mobility of organic contaminants."( Influence of anionic, cationic and nonionic surfactants on adsorption and desorption of oxytetracycline by ultrasonically treated and non-treated multiwalled carbon nanotubes.
Oleszczuk, P; Xing, B, 2011
)
0.37
" OTC present as a cation, zwitterions, or net negatively charged ion in soils complicates predicting its sorption characteristics and potential bioavailability and toxicity."( Characteristics of oxytetracycline sorption and potential bioavailability in soils with various physical-chemical properties.
Dolhi, JM; He, J; Kong, W; Li, C; Li, S; Qiao, M, 2012
)
0.38
" They are often poorly absorbed with a significant fraction being excreted in manure that can subsequently result in environmental contamination."( Effect of temperature, pH and illumination on abiotic degradation of oxytetracycline in sterilized swine manure.
Boonsaner, M; Hawker, DW; Ratasuk, N, 2012
)
0.38
" Mycotoxin-detoxifying agents can thus interact with the oral bioavailability of antibiotics depending on the antibiotic and detoxifying agent, with possible adverse effects on the health of animals and humans."( Efficacy and safety testing of mycotoxin-detoxifying agents in broilers following the European Food Safety Authority guidelines.
Croubels, S; De Backer, P; De Baere, S; De Saeger, S; Devreese, M; Eeckhout, M; Goossens, J; Hautekiet, V; Osselaere, A; Vandenbroucke, V; Watteyn, A, 2012
)
0.38
" Further studies will be required to determine whether rifampin reduces oxytetracycline bioavailability in this system, as suggested by human studies using other tetracycline-rifampin combinations."( Efficacy of three-week oxytetracycline or rifampin monotherapy compared with a combination regimen against the filarial nematode Onchocerca ochengi.
Bah, GS; Makepeace, BL; Srivastava, A; Tanya, VN; Trees, AJ; Ward, EL, 2014
)
0.4
"A nanocomposite based on chitosan and montmorillonite was developed as carrier to improve oral bioavailability of oxytetracycline."( Intestinal permeability of oxytetracycline from chitosan-montmorillonite nanocomposites.
Aguzzi, C; Bonferoni, C; Cerezo, P; Salcedo, I; Sánchez-Espejo, R; Sandri, G; Viseras, C, 2014
)
0.4
" Tylosin, a hydrosoluble compound, with a molecular weight of 916 g/mol, has a low oral bioavailability and a low apparent volume of distribution, too."( Withdrawal times of oxytetracycline and tylosin in eggs of laying hens after oral administration.
Araya-Jordán, C; Cornejo, J; Iragüen, D; Maddaleno, A; Muñoz, R; Pizarro, N; San Martín, B, 2014
)
0.4
" Bioavailability was 76."( Pharmacokinetics of oxytetracycline in broiler chickens following different routes of administration.
Barski, D; Grabowski, T; Jaroszewski, JJ; Jasiecka, A; Ziółkowski, H; Zuśka-Prot, M, 2016
)
0.43
"The absolute bioavailability of OTC in the group of birds exposed to higher ions concentration was reduced (8."( Metal ion-oxytetracycline pharmacokinetic interactions after oral co-administration in broiler chickens.
Grabowski, T; Jaroszewski, JJ; Jasiecka, A; Przybysz, J; Ziółkowski, H; Zuśka-Prot, M, 2016
)
0.43
"The aim of this study was to determine to what extent the ions present in hard water (125 mg/L of MgCl2 and 500 mg/L of CaCl2) may intensify the feed-induced decrease in oxytetracycline (OTC) absorption rate in broiler chickens after single oral administration at a dose of 15 mg/kg."( Hard water may increase the inhibitory effect of feed on the oral bioavailability of oxytetracycline in broiler chickens.
Grabowski, T; Jaroszewski, JJ; Madej-Śmiechowska, H; Maślanka, T; Ziółkowski, H, 2019
)
0.51
" Statistically significant lower absolute bioavailability was achieved when hard water was used and/or animals were fed."( Impact of water hardness on oxytetracycline oral bioavailability in fed and fasted piglets.
Amanto, FA; Decundo, JM; Diéguez, SN; Fernández Paggi, MB; Martínez, G; Pérez Gaudio, DS; Romanelli, A; Soraci, AL, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"This research focuses on the effects of the composting process on oxytetracycline antibiotic degradation and the bioavailability of arsenic and copper."( Changes in Arsenic and Copper Bioavailability and Oxytetracycline Degradation during the Composting Process.
Cheng, D; Feng, Y; Li, Z; Liu, Y; Shehata, E, 2019
)
0.51
" The study revealed the drug kinetics best followed the enterohepatic circulation model with very poor bioavailability and low blood concentration after oral administration."( Pharmacokinetics, bioavailability and withdrawal period of antibiotic oxytetracycline in catfish Pangasianodon hypophthalmus.
Baitha, R; Bera, AK; Das, BK; Das, N; Krishna, N; Kumar, A; Manna, SK; Nag, SK; Patil, PK; Ravindran, R; Sarkar, DJ, 2022
)
0.72
" With these promising results, the true effect of DOM PARAFAC components on the degradation of OTC can be revealed, which is helpful for addressing antibiotic contamination to improve the bioavailability of compost products."( Characteristics of oxytetracycline stress-sensitive microbe-dissolved organic matter component interactions during composting.
Cui, H; Wei, Z; Zhang, X; Zhao, M; Zhao, R, 2022
)
0.72
" The results showed that sulfadimethoxine is well absorbed and accumulates in the muscle, kidneys and liver, where concentrations were higher than the maximum residue limits (MRLs) authorised in EU legislation."( Validation of a LC-MS/MS method for the quantitative analysis of four antibiotics in pig tissues and plasma to assess the risk of transfer of residues to edible matrices after exposure to cross-contaminated feed.
Gaugain, M; Hurtaud-Pessel, D; Lagree, MP; Laurentie, M; Perrin-Guyomard, A; Sanders, P; Santos-Santórum Suárez, C; Taillandier, JF; Viel, A, 2022
)
0.72
" Bioavailability assessment has gradually attracted more attention in order to provide a more realistic assessment of human health risks."( Prediction models and major controlling factors of antibiotics bioavailability in hyporheic zone.
Cheng, Y; Feng, R; Hu, R; Li, H; Zhang, J; Zhou, M; Zhu, T, 2023
)
0.91
"Copper (Cu) and tetracyclines (TCs) often coexist in agricultural soils because of the use of manures on farmland; however, the influence of Cu on the bioavailability of TCs is still unclear, especially for cases with aging Cu."( Influence of copper and aging on freely dissolved tetracycline concentration in soil.
Guo, R; He, J; Li, L; Li, X; Ma, W; Wang, Y; Zhu, D, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" if they had been treated in the beginning of this therapy with a higher dosage of tetracycline."( [On the influence of a special preparation of oxytetracycline and sodiumbituminosulfonates on amount and composition of skin surface lipids in acne vulgaris (author's transl)].
Friederich, HC; Gloor, M; Josephs, H, 1975
)
0.25
" Blood levels after dosing with 3 different commercial products containing oxytetracycline proved the non-equivalence of these products."( Blood levels of oxytetracycline in dogs after oral administration.
Immelman, A, 1977
)
0.26
" old and 1 week old chicks at a dosage of 5 mg."( A study in the pharmacodynamics of oxytetracycline in the chicken.
Black, WD, 1977
)
0.26
" A dosage regimen (intravenous route of drug administration), based on overall elimincation rate constant (0."( Pharmacokinetics and dosage of oxytetracycline in dogs.
Baggot, JD; Kerr, KM; Kowalski, JJ; Powers, JD; Powers, TE, 1978
)
0.26
"5%) were reactors; 110 of the reactors (from 7 herds) were tested after being treated orally for 45 days with chlortetracycline or oxytetracycline at a calculated daily dosage of 11 mg/kg of body weight, and all were seronegative."( Anaplasmosis: a regional serologic survey and oral antibiotic therapy in infected herds.
Stauber, EH; Sweet, VH, 1978
)
0.26
"A trial comparing the efficacy of three different tetracyclines, each in two different dosage regimens, in the treatment of non-specific urethritis is described."( Management of non-specific urethritis in men. Evaluation of six treatment regimens and effect of other factors including alcohol and sexual intercourse.
Alergant, CD; Annels, EH; Arya, OP; Carey, PB; Ghosh, AK; Goddard, AD, 1978
)
0.26
"Isoprenaline dosed 50 mg/kg was injected intraperitoneally into rats aged 42 days, 3 months, and 18 months."( Age-dependent variations in the intensity of isoprenaline-induced myocardial lesions in rats.
Kalincák, M; Kohút, A; Machán, V; Nicák, A; Vilcek, S, 1978
)
0.26
" Moreover, the dosage of the antibiotic oxytetracycline hydrochloride as well as the titre of the immune serum were found to be factors in the prevention of AR."( [Measures to be adopted in the prevention and treatment of atrophic rhinitis in piglets under field conditions (author's transl)].
Bercovich, Z; De Jong, MF, 1977
)
0.26
" After the strips had been contracted by 3x10-6M phenylephrine, a concentration which was able to produce an about 90% maximal contraction, dose-response curves to the relaxant effect of isoprenaline were determined in the absence and in the presence of U-0521 (10-4M)."( Relation between the amount of smooth muscle of venous tissue and the degree of supersensitivity to isoprenaline caused by inhibition of catechol-O-methyl transferase.
Azevedo, I; Cardoso, W; Guimarães, S; Oliveira, MC, 1975
)
0.25
" It was concluded that OTC is an antibiotic of potential interest in camels and that a dosage regimen of 10 mg."( Pharmacokinetics and local tolerance of a long-acting oxytetracycline formulation in camels.
Oukessou, M; Toutain, PL; Uccelli-Thomas, V, 1992
)
0.28
"Differences in bioavailability of many drugs from their various dosage forms have been shown to be relatively common in human medicine."( Bioavailability and bioinequivalence of drug formulations in small animals.
Watson, AD, 1992
)
0.28
" Five of the pigs were fasted 18 h prior to dosing and five of the pigs were fed ad libitum prior to dosing."( Chlortetracycline in swine--bioavailability and pharmacokinetics in fasted and fed pigs.
Bane, DP; Bevill, RF; Hall, WF; Kilroy, CR; Koritz, GD, 1990
)
0.28
" This suggests that there is about a 14-fold variation in t1/2 across the size range of terrestrial homoeotherms, and provides a guide to dosage regime for species in which oxytetracycline kinetics have not been studied."( Interspecies variation in the plasma halflife of oxytetracycline in relation to bodyweight.
Kirkwood, JK; Widdowson, MA, 1990
)
0.28
"Oxytetracycline (OTC) concentration in plasma and tissues, plasma pharmacokinetics, depletion from tissue, and toxicity were studied in 30 healthy calves after IM administration of a long-acting OTC preparation (40 mg/kg of body weight) at double the label dosage (20 mg/kg)."( Oxytetracycline pharmacokinetics, tissue depletion, and toxicity after administration of a long-acting preparation at double the label dosage.
TerHune, TN; Upson, DW, 1989
)
0.28
"Four pigs were used in a 2 X 2 crossover study to determine plasma oxytetracycline (OTC) concentration and OTC pharmacokinetic variables after IM administration of 2 OTC preparations--long acting OTC and a 100-mg of OTC/ml solution (OTC-LA and OTC-100, respectively)--at a dosage of 20 mg/kg of body weight."( Plasma concentrations of oxytetracycline in swine after administration of the drug intramuscularly and orally in feed.
Bane, DP; Bevill, RF; Hall, WF; Kniffen, TS; Koritz, GD, 1989
)
0.28
" Hence oxytetracycline residues were the most persistent in these types of foods, according to our dosage scheme."( Chloramphenicol and oxytetracycline residues in milk and tissues from cows and bullocks treated with an injectable formulation.
Guillot, P; Mourot, D; Sanders, P,
)
0.13
" These results provide a basis for devising appropriate oxytetracycline dosage regimes for the species."( Pharmacokinetics of oxytetracycline in clinical cases in the red-necked wallaby (Macropus rufogriseus).
Gulland, FM; Kirkwood, JK; Needham, JR; Vogler, MG, 1988
)
0.27
" Based on pharmacokinetic changes, an adjustment of dosage is indicated for oxytetracycline in the newborn calf as compared to the older calf or adult."( Comparative pharmacokinetics of gentamicin, neomycin and oxytetracycline in newborn calves.
Barto, PB; Burrows, GE; Martin, B, 1987
)
0.27
" Based on these kinetic data, a dosage of 15 mg of OTC/kg, every 8 hours was developed."( Pharmacokinetics of oxytetracycline hydrochloride in rabbits.
Clark, CH; McElroy, DE; Ravis, WR, 1987
)
0.27
" The first group of seven calves received oxytetracycline at a dosage rate of 10 mg kg-1 once a day."( Antibiotic serum activities against bacterial isolations from cases of bovine pneumonic pasteurellosis in feedlot calves.
Fabian, B; Van Amstel, SR; Vervoort, P; Witcomb, MA, 1987
)
0.27
" Repeated dosing resulted in accumulation of OTC in TCF."( Penetration of oxytetracycline into tissue-cages in calves.
Bengtsson, B; Jacobsson, SO; Luthman, J, 1986
)
0.27
" This disease model offers potential for use in pharmacokinetic and target tissue drug concentration studies and for dosage titration of drugs intended for treatment of bacterial pneumonias."( Characterization of a Pasteurella multocida (serotype B) bovine pneumonic pasteurellosis model and the effect of antimicrobials during peracute infection.
April, M; Carnevale, RA; Furrow, RD; Gaines, SA; Guarnieri, JA; McRae, DT; Parbuoni, EL, 1986
)
0.27
"Timed-pregnant CD rats and CD-1 mice were dosed by gavage with oxytetracycline hydrochloride (OXT) in corn oil on gestational days (gd) 6-15 (0, 1200, 1350, or 1500 mg/kg/day for rats; 0, 1325, 1670, or 2100 mg/kg/day for mice)."( The developmental toxicity of orally administered oxytetracycline in rats and mice.
Kimmel, CA; Ledoux, TA; Marr, MC; Morrissey, RE; Paschke, LL; Price, CJ; Reel, JR; Tyl, RW, 1986
)
0.27
"Oxytetracycline (OTC) concentrations on plasma and milk of dairy cows were determined following a single intramuscular injection of five oxytetracycline-20% formulations at a dosage of approximately 10 mg/kg."( Comparative pharmacokinetics, bioavailability and renal clearance of five parenteral oxytetracycline-20% formulations in dairy cows.
Breukink, HJ; Driessens, F; Mevius, DJ; Nouws, JF; Verkaik, R; Vree, TB, 1986
)
0.27
"Four recently weaned pigs were dosed orally with oxytetracycline."( The effects of oxytetracycline on the intestinal Escherichia coli flora of newly weaned pigs.
Hampson, DJ; Hampson, E; Hinton, M; Linton, AH, 1985
)
0.27
" The highest level completely inhibited parasite replication and antibody formation; the same was observed in one animal dosed at 10 mg/kg but the remainder, plus those treated at 5 mg/kg, developed both low parasitaemia and high antibody titres."( Inhibition of Babesia divergens in cattle by oxytetracycline.
Elliott, CT; Kenny, J; Taylor, SM, 1986
)
0.27
" Dosage regimens to maintain minimum OTC concentration of 5 micrograms/ml of serum were calculated from the t 1/2 and Vd values obtained, using steady-state pharmacokinetics."( Pharmacokinetics of a long-acting oxytetracycline preparation in ring-necked pheasants, great horned owls, and Amazon parrots.
Graham, DL; Schwark, WS; Shin, SJ; Teare, JA, 1985
)
0.27
" Results obtained using this method for both bulk and dosage forms of oxytetracycline are in accord with the results of the microbiological assays."( Reversed-phase high-performance liquid chromatographic method for the assay of oxytetracycline.
Barnes, WN; Bates, LJ; Ray, A, 1985
)
0.27
" Used in high dosage by the intraventricular as well as the intravenous route, this drug might be successful in the treatment of further cases of primary amoebic meningoencephalitis."( Sensitivity to amphotericin B of a Naegleria sp. isolated from a case of primary amoebic meningoencephalitis.
Carter, RF, 1969
)
0.25
" Despite world-wide knowledge of these effects, millions of prophylactic injections of equine tetanus antitoxin are given annually, and it is continually proposed that the dosage be increased in order to obtain higher "protective" levels in the serum, a procedure which would increase the incidence and severity of reactions."( Progress in tetanus prophylaxis: the advent of human antitoxin.
Perey, BJ, 1966
)
0.24
" Although HPO alone is primarily bacteriostatic, combined therapy with antibiotics and HPO may be useful against bacterial infections because the therapeutic effectiveness of a maximal dosage of antibiotic could be increased."( Enhancement of antibiotic activity against Staphylococcus aureus by exposure to hyperbaric oxygen.
Bornside, GH, 1967
)
0.25
" Dose-response experiments with oxytetracycline and with the combination of the antibiotic with nitrite revealed an apparent no-effect level at 2 X 50 to 2 X 500 mg/kg."( Mutagenicity of oxytetracycline.
Blitek, D; Gajcy, H; Koziorowska, J; Pieńkowska, K, 1983
)
0.27
"50 dairy cows were alternately either given no perinatal treatment or were given an intramuscular injection of oxytetracycline in a 2-pyrrolidone base at a dosage rate of 20 mg/kg body mass."( On the use of oxytetracycline in reducing the incidence of metritis in dairy cows.
Henning, AC; Marnewick, JJ; Moore, CW, 1984
)
0.27
" Computer-simulated uterine tissue concentrations of OTC, after twice daily IV doses of 11 mg of OTC/kg of body weight, indicated that this dosage regimen would provide postpartum uterine tissue concentrations greater than 5 micrograms/g during most of the dosage interval."( Distribution of oxytetracycline in the healthy and diseased postpartum genital tract of cows.
Bevill, RF; Bretzlaff, KN; Davis, LE; Gustafsson, BK; Koritz, GD; Ott, RS, 1983
)
0.27
" Computer-simulated genital tissue concentrations of OTC after twice daily IV doses of 11 mg/kg indicated that this dosage regimen would provide postpartum uterine tissue concentrations greater than 5 micrograms/g throughout the dosage interval in all tissues, except the uterine wall."( Distribution of oxytetracycline in genital tract tissues of postpartum cows given the drug by intravenous and intrauterine routes.
Bevill, RF; Bretzlaff, KN; Davis, LE; Gustafsson, BK; Koritz, GD; Ott, RS, 1983
)
0.27
"Treatment of adult Anaplasma carrier cows, with long-acting oxytetracycline at dosage levels generally successful in eliminating infection, was unsuccessful when the treatment was preceded or accompanied by a 2nd exposure to A marginale on days 0, 7, or 14 before treatment."( Influence of a second Anaplasma exposure on the success of treatment to eliminate Anaplasma carrier infections in cattle.
Kuttler, KL, 1983
)
0.27
" Seemingly, current concepts of antibiotic dosages and dosage intervals may be inadequate because they are based on blood and tissue values of healthy animals."( Oxytetracycline concentrations in healthy and diseased calves.
Ames, TR; Larson, VL; Stowe, CM, 1983
)
0.27
" The two groups receiving a therapeutic dosage of oxytetracycline had the most quickly declining body temperatures and the highest average body weights post-challenge."( Subtherapeutic tetracycline effects on recovery patterns of calves after Salmonella typhimurium challenge.
Avens, JS; Johnson, DE; Remillard, RL, 1981
)
0.26
" Computer-stimulated IV multiple doses of OTC at 11 mg/kg every 12 hours and 11 mg/kg every 24 hours suggested that the former dosage regimen could provide uterine tissue concentrations greater than 5 microgram/ml during the dosage interval, whereas the latter could provide such concentrations for only the first 12 hours of a 24-hour dosage interval."( Distribution of oxytetracycline in the genital tract of cows.
Bevill, RF; Bretzlaff, KN; Davis, LE; Gustafsson, BK; Koritz, GD; Lock, TF; Ott, RS; Shawley, RV, 1982
)
0.26
" Comparison of the area under the serum curves gave mean values of 117% for tetracycline and of 53% for chlortetracycline relative to oxytetracycline (arbitrarily fixed at 100%) after identical oral dosage of the three tetracyclines."( Pharmacokinetics of oxytetracycline and therapeutic implications in veal calves.
Galeazzi, RL; Nicolet, J; Schifferli, D; Wanner, M, 1982
)
0.26
"Oxytetracycline (OTC) was administered IV to 3 clinically normal horses at a dosage of 10 mg of OTC/kg of body weight."( Plasma and tissue concentrations of oxytetracycline in the horse after intravenous administration.
Larson, VL; Stowe, CM, 1981
)
0.26
"Six adult mares were given a single intravenous injection of oxytetracycline HCl (50 mg/ml) at a dosage of 5 mg/kg."( Oxytetracycline hydrochloride in the horse: serum, synovial, peritoneal and urine concentrations after single dose intravenous administration.
Brown, MP; Farver, TB; Kelly, RH; Knight, HD; Stover, SM, 1981
)
0.26
" The dosage of the antibiotic was adjusted to obtain plasma concentrations comparable with human therapeutic levels."( Effects of oxytetracycline on mineralization of bone in young rats.
Engesaeter, LB; Langeland, N; Underdal, T, 1980
)
0.26
" Following recovery, oxytetracycline was given at a dosage of 25 mg kg-1 body weight intraperitoneally on the day of loading and on the fourteenth day of the loading regimen."( The response of bone to external loading regimens.
MacLeod, K; McDonald, F; Yettram, AL, 1994
)
0.29
"Three adult mini-pigs were employed to assess the effects of a twice daily dosage (40 mg kg-1) of oxytetracycline hydrochloride (OTC) and a combination of OTC with (0."( Bromhexine plus oxytetracycline: the effect of combined administration upon the rheological properties of mucus from the mini-pig.
Loveday, BE; Marriott, C; Martin, GP, 1993
)
0.29
" For oxytetracycline, flucloxacillin and amoxycillin, the conventional bioavailability parameters indicated partial equivalence whereas using the te and to parameters, more realistic indications of the possible extent of the performance of a drug from dosage forms were obtained than with the conventional bioequivalence parameters."( The application of new bioavailability parameters in the bioequivalence testing of antimicrobial agents.
Ellis, SM; Koeleman, HA; Steyn, HS; Wessels, JC, 1993
)
0.29
"Simple assays for extraction and determination of the concentrations of the antibiotics oxytetracycline, oxolinic acid, and flumequine in a drug dosage form for farmed fish are described."( Extraction and analysis by high-performance liquid chromatography of antibiotics in a drug delivery system for farmed fish.
Rogstad, A; Weng, B, 1993
)
0.29
" A dose-response inhibition of antibacterial activity to high concentrations of OTC (500 to 1,000 micrograms/ml) was observed."( In vitro modulation of bovine blood neutrophils and mononuclear cells by oxytetracycline.
Farrell, DE; Henderson, M; Myers, MJ, 1995
)
0.29
" coli flora of young broiler chickens after oral administration at a dosage equivalent to a prophylactic course of treatment."( [Resistance to tetracycline of E. coli of chicken intestines after prophylactic treatment of animal feed with bioptivet GB].
Eggerding, B; Fries, R; Kobe, A; Skubich, B, 1995
)
0.29
"In view of the unpredictability of results of antibiotic therapy of bovine dermatophilosis and following the report of successful use of 10% formalin administered intravenously at the dosage of 20 ml per 100 kg body weight, a trial was undertaken to evaluate the latter treatment in naturally-occurring dermatophilosis in a group of Friesian crossbred cattle."( Chemotherapy of dermatophilosis--a preliminary study.
Aning, KG; Koney, EB, 1996
)
0.29
" It can be concluded that the long-acting formulations provide the advantage of a longer dosage interval when administered to pigs by intramuscular injection in the neck region at a dose of 20 mg/kg body weight."( Comparison of the pharmacokinetics and local tolerance of three injectable oxytetracycline formulations in pigs.
Baggot, JD; Banting, AL, 1996
)
0.29
"The objective of this study was to determine the oxytetracycline residues in milk from cows with clinical mastitis dosed with two extra-label routes of oxytetracycline administration not only during antibiotic's treatment (5 days), but also six days after treatment by use of a liquid chromatography method of testing with a detection limit of 20 ppb."( [Oxytetracycline in the milk of dairy cows with clinical signs of mastitis during the lactation period].
Burdová, O; Cabadaj, R; Dudriková, E; Sokol, J; Turek, P, 1996
)
0.29
" The alterations caused by dehydration on the disposition kinetics of the drug should be considered for better definition of dosage regimens for sick, dehydrated animals."( Effect of dehydration on the pharmacokinetics of oxytetracycline hydrochloride administered intravenously in goats (Capra hircus).
Elsheikh, HA; Eltayeb, IB; Osman Intisar, AM; Salam Abdullah, A, 1998
)
0.3
"The pharmacokinetics and dosage regimen of oxytetracycline were determined in healthy and febrile cross-bred calves following its single intravenous administration (10 mg kg-1)."( Influence of Escherichia coli endotoxin induced fever on the pharmacokinetics and dosage regimen of oxytetracycline in cross-bred calves.
Nauriyal, DC; Sharma, SK; Singh, RP; Srivastava, AK, 1998
)
0.3
"The pharmacokinetic behaviour of oxytetracycline (OTC) was studied in 11 sheep after intravenous and intramuscular administration at a single dosage of 20 mg kg(-1) bodyweight."( Pharmacokinetics of oxytetracycline after intramuscular administration with lidocaine in sheep, comparison with a conventional formulation.
Carceles, CM; Guimerá, ME; Moreno, L; Serrano, JM,
)
0.13
"A two-way crossover study was conducted in crossbred male calves (6-8 months old) to determine the bioavailability, pharmacokinetics and dosage regimens for a long-acting formulation of oxytetracycline (OTC-LA)."( Some pharmacokinetic parameters and dosage regimens for a long-acting formulation of oxytetracycline in 6- to 8-month-old male calves.
Kumar, R; Malik, JK, 1998
)
0.3
" The above changes may necessitate changes in the dosage regimen of oxytetracycline used to treat Theileria infections in cattle under field conditions."( Effects of experimentally induced Theileria annulata infection on the pharmacokinetics of oxytetracycline in cross-bred calves.
Kumar, R; Malik, JK,
)
0.13
" Oxytetracycline concentrations in egg components were determined daily during a 2-d pretreatment control period, the 5-d dosing period, and following drug withdrawal."( Oxytetracycline transfer into chicken egg yolk or albumen.
Donoghue, DJ; Hairston, H, 1999
)
0.3
" These changes may necessitate alterations in the dosage regimen of oxytetracycline used to treat Theileria annulata infections in cattle under field conditions."( Influence of experimentally induced theileriosis (Theileria annulata) on the pharmacokinetics of a long-acting formulation of oxytetracycline (OTC-LA) in calves.
Kumar, R; Malik, JK, 1999
)
0.3
" Blood, pancreatic tissue (for enzyme dosage and morphological study), and duodenal fluid were extracted following anesthesia."( Effects of oxytetracycline on the rat exocrine pancreas.
Almaraz, A; Belmonte, A; Caro-Patón, A; del Olmo Martinez, ML; Lorenzo, C; Pastor, L, 1999
)
0.3
"5 microg/ml were present 48 hr after initial dosing for all elephants (i."( Serum oxytetracycline concentrations in African elephant (Loxodonta africana) calves after long-acting formulation injection.
Bush, M; Papich, MG; Raath, JP; Stoskopf, MK, 2000
)
0.31
" The antibiotic was administered to five healthy Friesian cows at a dosage of 3g/head in the early post partum phase."( Pharmacokinetics and residual behaviour in milk of oxytetracycline in cows following administration of uterine pessaries.
Ermini, L; Roncada, P; Schleuning, A; Stracciari, GL; Strocchia, A, 2000
)
0.31
" Underdosing with trypanocides appeared to be uncommon and the indications were that farmers generally gave the drugs at dosage rates above the recommended standard dose."( The use of trypanocides and antibiotics by Maasai pastoralists.
Mwendia, C; Okech, G; Roderick, S; Stevenson, P, 2000
)
0.31
" dosing had terminal slope half-lives of 20."( Serum pharmacokinetics and tissue and milk residues of oxytetracycline in goats following a single intramuscular injection of a long-acting preparation and milk residues following a single subcutaneous injection.
Babish, JG; Bulgin, M; Craigmill, AL; Lane, M; Payne, MA; Wetzlich, S, 2002
)
0.31
" The dosage and duration of treatment were correct in only 6% of cases."( Drugs in the parallel market for the treatment of urethral discharge in Dakar: epidemiologic investigation and physicochemical tests.
Ba, C; Badiane, M; Gueye, TS; Sow, PS; Sy, E; Toure, L, 2002
)
0.31
" The results of the in vivo evaluation of the formulation in sheep indicated that a controlled release biodegradable injectable dosage form of OTC for food animals is feasible."( Controlled release of oxytetracycline in sheep.
Aksornkoae, N; Boring, JG; Cooper, RC; Johnson, JR; Laizure, SC; Peng, Y; Scruggs, D; Shukla, AJ; Sun, Y, 2002
)
0.31
" We found no studies which compared the efficacy of the two dosage forms."( Comparative efficacy of two anti-bacterial/anti-inflammatory formulations (Auricularum otic powder and Dex-Otic drops) in the medical treatment of otitis externa.
Cahani, B; Hadar, T; Lapidot, M; Nageris, B; Shevro, J; Yaniv, E; Zegerman, C, 2002
)
0.31
" This simple PBPK model well predicted OTC residues in sheep tissues after intramuscular dosing with a long-acting preparation and may find use for other species and other veterinary drugs."( A physiologically based pharmacokinetic model for oxytetracycline residues in sheep.
Craigmill, AL, 2003
)
0.32
"Forty cases of gonococcal urethritis were treated with oxytetracycline using various dosage schedules; there were 37 cures and three failures."( TREATMENT OF URETHRITIS IN MALES WITH OXYTETRACYCLINE.
ETHIER, J; SYLVESTRE, L, 1963
)
0.24
" These data were integrated with production records for sparids, drug dosage regimes and treatment frequency information to calculate potential annual drug release to the aquatic environment from Greek fish farms."( Potential drug (oxytetracycline and oxolinic acid) pollution from Mediterranean sparid fish farms.
Alexis, M; Nengas, I; Rigos, G; Troisi, GM, 2004
)
0.32
" Organic impurities separated from actual OTC fermentation waste liquor by ultrafiltration were dosed into a pure OTC solution at various concentrations."( Crystallization of oxytetracycline from fermentation waste liquor: influence of biopolymer impurities.
Li, SZ; Li, XY; Wang, D, 2004
)
0.32
" Truly dissolved fractions in the water column during dosing were 16% in the settling pond, 64% in the receiving segment, and approximately 78% in the river segments."( Fate of oxytetracycline in streams receiving aquaculture discharges: model simulations.
Pedersen, JA; Rose, PE, 2005
)
0.33
" Clear dose-response relations were determined with SIR when the short-term incubation of 4h was extended into the growth phase of the microorganisms (24 and 48 h)."( Effects of sulfonamide and tetracycline antibiotics on soil microbial activity and microbial biomass.
Beck, IC; Thiele-Bruhn, S, 2005
)
0.33
" Tetracycline, oxytetracycline, chlortetracycline and minocycline all effectively induced the resulting Escherichia coli MC4100/pTGM biosensor and similar dose-response characteristics were recorded by flow cytometry for all four compounds."( Construction of an extended range whole-cell tetracycline biosensor by use of the tet(M) resistance gene.
Bahl, MI; Hansen, LH; Sørensen, SJ, 2005
)
0.33
" Based on the similarity of these pharmacokinetic parameters, it appears that quail could be used as a model species to predict the appropriate OTC dosing regimen for small psittacine birds."( Investigation of Japanese quail (Coturnix japonica) as a pharmacokinetic model for cockatiels (Nymphicus hollandicus) and Poicephalus parrots via comparison of the pharmacokinetics of a single intravenous injection of oxytetracycline hydrochloride.
Craigmill, AL; Kass, PH; Nugent-Deal, J; Osofsky, A; Tell, LA; Wetzlich, SE, 2005
)
0.33
" Therefore, the aim of this project was to determine whether it was possible to distinguish between a single therapeutic dose of a tetracycline (permitted under the standards) and both multiple therapeutic dosing and prophylactic dosing (not permitted)."( Verification of compliance with organic meat production standards by detection of permitted and nonpermitted uses of veterinary medicines (tetracycline antibiotics).
Ashwin, H; Kelly, M; Sharman, M; Tarbin, JA, 2006
)
0.33
" Our study indicates that the reverse micellar system has potential applications in solubilizing and stabilizing oxytetracycline HCl, thereby contributing to the development of its dosage forms."( Degradation patterns of tetracycline antibiotics in reverse micelles and water.
Sah, H, 2006
)
0.33
"Lack of dosing information of the major antibiotics known as oxytetracycline (OTC) for the Pacific white shrimp (Litopenaeus vannamei) could have harmful impact on aquaculture in Thailand."( The complete analysis of oxytetracycline pharmacokinetics in farmed Pacific white shrimp (Litopenaeus vannamei).
Chandumpai, A; Chiayvareesajja, S; Faroongsarng, D; Theapparat, Y, 2006
)
0.33
" The dosage injected was 5 cm(3) of the drug (25 mg) in 5 cm(3) of anaesthesia for the knee, 2 cm(3) with 1 cm(3) of anaesthesia for the elbow and 1 cm(3) plus 1 cm(3) of anaesthesia for the ankle."( Chemical synoviorthesis with oxytetracycline clorhydrate (Emicine) in recurrent haemarthrosis.
Boadas, A; Cedeño, M; Chacal B, F; De Bosch, NB; De Saez, AR; Fernández-Palazzi, F; Maldonado, JC, 2008
)
0.35
" The dose of 4 g/kg of feed for 5 consecutive days can be recommended for therapeutic dosage regimen in giant freshwater prawn aquaculture."( Distribution and residue depletion of oxytetracycline in giant freshwater prawn (Macrobrachium rosenbergii).
Imsilp, K; Klangkaew, N; Kumagai, S; Kusutjarit, N; Poapolathep, A; Poapolathep, S; Wannapat, N, 2008
)
0.35
" A dosing interval of 6-11 h is recommended to achieve therapeutic drug concentration in those structures."( Tissue distribution of dexamethasone in canine ocular compartments following topical application of dexamethasone-21-isonicotinate and oxytetracycline HCl.
Bäumer, W; Kaiser, T; Kietzmann, M; Werner, A,
)
0.13
" This inhibition was clearly enhanced with the increase exposure dosage of antibiotic and could not be eliminated during 30 d incubation."( Influence of oxytetracycline on the structure and activity of microbial community in wheat rhizosphere soil.
Yang, Q; Zhang, H; Zhang, J; Zhu, K, 2009
)
0.35
"05) inhibited by OTC, and there was a good dose-response relationship between the OTC concentration and inhibition rates."( [Ecotoxicological effects of oxytetracycline on wheat (Triticum aestivum) based on seed germination and seedling development].
An, J; Liu, WT; Zhou, QX, 2009
)
0.35
" Soil fertility level had obvious effects on the dose-response relations between oxytetracycline and soil microbial number and activity."( [Effects of pig manure and oxytetracycline on microbial number and activity in soils with different fertility levels].
Liu, ZY; Zhang, MK, 2009
)
0.35
"The ozonation performance of wastewater treatment plant secondary effluent of oxytetracycline (OTC) manufacturing wastewater was investigated in terms of ozone dosage and initial pH levels when OTC contributed to a negligible fraction in the chemical oxygen demand (COD) ingredients of the medium-organic-strength wastewater with low biodegradability."( Ozonation performance of WWTP secondary effluent of antibiotic manufacturing wastewater.
Cui, C; Liang, Q; Xia, X; Yang, F; Zheng, S, 2010
)
0.36
"The main objective of this study was to determine the optimal oxytetracycline hydrochloride (OTC) dosage for otolith marking in Dicentrarchus labrax and Diplodus puntazzo."( Oxytetracycline hydrochloride vital labelling revisited: the case of Dicentrarchus labrax and Diplodus puntazzo.
Grau, A; Morales-Nin, B; Palmer, M; Pastor, E; Pérez-Mayol, S, 2011
)
0.37
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
"Mixed populations of plasmid donor (Salmonella Typhimurium) and recipient (E coli) bacteria were assigned to 1 of 2 simulated oxytetracycline dosing regimens (high peak concentration-short elimination half-life [HC-SHL] or low peak concentration-long elimination half-life [LC-LHL]) or served as untreated control replicates."( Effects of two simulated oxytetracycline dosing regimens on horizontal transfer of antimicrobial resistance plasmids in an in vitro pharmacodynamic model.
Apley, MD; Coetzee, JF; Havel, JA; Lubbers, BV; Narayanan, SK; Peterson, GJ, 2011
)
0.37
" The methods were tested for QC of veterinary dosage forms (commercial powders and injections containing these antibiotics)."( Determination of neomycin and oxytetracycline in the presence of their impurities in veterinary dosage forms by high-performance liquid chromatography/tandem mass spectrometry.
Cservenák, R; Radulović, N; Vucićević-Prcetić, K,
)
0.13
" A safety study with 2 commercially available detoxifying agents and veterinary drugs showed innovative results with regard to the pharmacokinetics of 2 antibiotics after oral dosing in the drinking water."( Efficacy and safety testing of mycotoxin-detoxifying agents in broilers following the European Food Safety Authority guidelines.
Croubels, S; De Backer, P; De Baere, S; De Saeger, S; Devreese, M; Eeckhout, M; Goossens, J; Hautekiet, V; Osselaere, A; Vandenbroucke, V; Watteyn, A, 2012
)
0.38
" Serum was collected from nine fish at 1, 3, 6, 8, 10, 12, 15, and 22 d after dosing began."( Oxytetracycline pharmacokinetics in rainbow trout during and after an orally administered medicated feed regimen.
Kane, AS; Miller, RA; Pelsor, FR; Reimschuessel, R, 2012
)
0.38
" These data provide a basis for the rational use of carprofen with oxytetracycline in calves and indicate that no alteration to carprofen dosage is required when the drugs are co-administered."( Influence of oxytetracycline on carprofen pharmacodynamics and pharmacokinetics in calves.
Brentnall, C; Cheng, Z; Lees, P; McKellar, QA, 2013
)
0.39
"Use acetic acid as the media of ozone degradation of oxytetracycline (OTC), and effects of the initial dosing ratio of ozone/OTC, ozone flow, free radical scavenger, metal ions on the removal rate of OTC were investigated respectively."( [Degradation of oxytetracycline with ozonation in acetic acid solvent].
Li, SY; Li, XR; Wang, GX; Zhu, JP; Zhu, YP, 2012
)
0.38
" Here we show the risk assessment for oxytetracycline (OTC) use in seawater and its subsequent transfer to sediment, and illustrate that the sediment bacterial community was stable against OTC at dosed concentrations."( Risk assessment of oxytetracycline in water phase to major sediment bacterial community: a water-sediment microcosm study.
Ogo, M; Suga, N; Suzuki, S, 2013
)
0.39
" A 6-month regimen of oxytetracycline with monthly dosing was strongly adulticidal, while 3-week and 6-week regimens exhibited weaker adulticidal effects."( Efficacy of three-week oxytetracycline or rifampin monotherapy compared with a combination regimen against the filarial nematode Onchocerca ochengi.
Bah, GS; Makepeace, BL; Srivastava, A; Tanya, VN; Trees, AJ; Ward, EL, 2014
)
0.4
" The OTC residual levels in muscle showed a dose-response relationship."( Transferability of oxytetracycline (OTC) from feed to carp muscle and evaluation of the antibiotic effects on antioxidant systems in liver and kidney.
Abete, MC; Ciccotelli, V; Dörr, AJ; Elia, AC; Gasco, L; Gili, M; Natali, M; Pacini, N; Prearo, M, 2014
)
0.4
" To examine whether antibiotic dosage defines the abundance of antibiotic-resistant bacteria in animal feed, we determined the concentration of parental compounds and epimers of oxytetracycline (OTC), doxycycline, tetracycline and chlortetracycline, as well as the abundance and resistance level of OTC-resistant bacteria in samples of fish (n = 21), poultry (n = 21), swine (n = 21), and shrimp feed (n = 21) marketed in Costa Rica."( Unravelling a vicious circle: animal feed marketed in Costa Rica contains irregular concentrations of tetracyclines and abundant oxytetracycline-resistant Gram-positive bacteria.
Alfaro, M; Chavarría, G; Granados-Chinchilla, F; Rodríguez, C, 2014
)
0.4
"62 g volatile suspended solid (VSS) sludges were varied to optimize bio-augmentation dosage (BAD), and appropriate bio-augmentation time (BAT) was determined."( Bio-augmentation for mitigating the impact of transient oxytetracycline shock on anaerobic ammonium oxidation (ANAMMOX) performance.
Guo, LX; Jin, RC; Liu, JH; Wang, HZ; Yang, BE; Zhang, QQ; Zhang, ZZ, 2014
)
0.4
" For most parameters measured, there was a clear linear dose-response to treatment with MCE."( Growth promotion in broilers by both oxytetracycline and Macleaya cordata extract is based on their anti-inflammatory properties.
Everaert, N; Khadem, A; Niewold, TA; Soler, L, 2014
)
0.4
"Research into the pharmacokinetics and residue elimination of oxytetracycline (OTC) is important both to determine the optimal dosage regimens and to establish a safe withdrawal time in fish."( Comparative pharmacokinetics of oxytetracycline in blunt-snout bream (Megalobrama amblycephala) with single and multiple-dose oral administration.
Chen, XX; Huang, C; Li, J; Li, RQ; Ren, YW; Shao, JH; Wu, ZX, 2015
)
0.42
" The objective of this study was to evaluate the efficacy of three oral dosage regimens (5, 10 and 20mg/kg body weight) of oxytetracycline (OTC) in drinking water over a five-day period on diarrhoea, faecal shedding of LI and average daily weight gain (ADG)."( A randomised clinical trial on the efficacy of oxytetracycline dose through water medication of nursery pigs on diarrhoea, faecal shedding of Lawsonia intracellularis and average daily weight gain.
Hjulsager, CK; Holm, A; Larsen, I; Nielsen, JP; Nielsen, SS; Olsen, JE, 2016
)
0.43
" Both formulations delivered therapeutic plasma concentrations of oxytetracycline for approximately 100% of their respective dosing intervals as recommended."( Pharmacokinetics of Short- and Long-acting Formulations of Oxytetracycline After Intramuscular Administration in Chickens.
Gberindyer, AF; Okpeh, ER; Semaka, AA, 2015
)
0.42
" morhua otoliths, chemically tagged with tetracycline at similar dosage to the historic otoliths."( Tetracycline marks visible in Baltic cod Gadus morhua otoliths stored for 40 years.
Bingel, F; Krumme, U, 2016
)
0.43
" Claws of 32 broilers treated with a therapeutic dosage of 10% OTC during 7 days were analysed."( Residue depletion of oxytetracycline (OTC) and 4-epi-oxytetracycline (4-epi-OTC) in broiler chicken's claws by liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Araya, D; Araya-Jordán, C; Briceño, C; Cornejo, J; Hidalgo, H; Maddaleno, A; Pokrant, E; San Martin, B, 2017
)
0.46
"For all organisms and all drugs investigated in this study, it is suggested that broth MICs should be adjusted by an appropriate scaling factor when used to determine pharmacokinetic/pharmacodynamic breakpoints for dosage prediction."( Impact of growth matrix on pharmacodynamics of antimicrobial drugs for pig pneumonia pathogens.
Dorey, L; Lees, P, 2017
)
0.46
" Determining potencies of tetracyclines in a physiological medium, such as FBS, is proposed, when the objective is correlation with pharmacokinetic data for dosage determination."( Differential susceptibility to tetracycline, oxytetracycline and doxycycline of the calf pathogens Mannheimia haemolytica and Pasteurella multocida in three growth media.
Lees, P; Mead, A; Mitchell, J; Pelligand, L; Rycroft, A; Standing, JF; Toutain, PL, 2019
)
0.51
" The antibiotic effects on MOP and methanotrophs were found to depend on the dosage and type of antibiotics."( Impacts of sulfanilamide and oxytetracycline on methane oxidation and methanotrophic community in freshwater sediment.
Tong, T; Xie, S, 2019
)
0.51
" These interactions may lead to impaired dosing and consequently decrease absorption."( Impact of water hardness on oxytetracycline oral bioavailability in fed and fasted piglets.
Amanto, FA; Decundo, JM; Diéguez, SN; Fernández Paggi, MB; Martínez, G; Pérez Gaudio, DS; Romanelli, A; Soraci, AL, 2019
)
0.51
"The impacts of antibiotic treatment and dosing regimen of an antibiotic on the swine respiratory microbiota are poorly defined."( Shifts in the nasal microbiota of swine in response to different dosing regimens of oxytetracycline administration.
Allen, HK; Alt, DP; Brockmeier, SL; Coetzee, JF; Hau, SJ; Holman, DB; Kellner, S; Loving, CL; Mou, KT; Trachsel, J, 2019
)
0.51
"84%) and post-OTC dosing (8."( Dietary influences of oxytetracycline on the growth and serum biomarkers of Oreochromis niloticus (L.).
Abraham, TJ; Boda, S; Julinta, RB; Patil, PK; Roy, A; Singha, J, 2019
)
0.51
" Anti-collagenolytic tear levels were not achieved at the timepoints evaluated or with the manufacturer-prescribed dosing frequency."( Tear film concentrations of topically applied 0.5% oxytetracycline ointment in normal canine eyes.
Cox, SK; Hendrix, DVH; Sigmund, AB; Ward, DA, 2020
)
0.56
" Dietary OTC reduced the antioxidant capacity of the liver and muscle tissues and down-regulated the expression of tumour necrosis factor-α, interleukin-1β, and heat shock protein-70 genes in the liver significantly during the dosing period."( Dietary therapeutic dose of oxytetracycline negatively influences the antioxidant capacity and immune-related genes expression in Nile tilapia Oreochromis niloticus (L.).
Abraham, TJ; Behera, BK; Julinta, RB; Kumar, KA; Paria, P; Patil, PK; Roy, A; Singha, J, 2021
)
0.62
"25% in 20-day dosing trials at 1× dose compared to control."( Accumulation and clearance of tissue residues and health status of Nile tilapia Oreochromis niloticus (L.) juveniles as influenced by the extended oral oxytetracycline-dosing.
Abraham, TJ; Julinta, RB; Krishna, EKN; Kumar, KA; Patil, PK; Rajisha, R; Roy, A; Singha, J, 2021
)
0.62
" The results show that the dosage of 5-10 mg/L TCMP daily effectively inhibited nitrification."( The effect of nitrification inhibitors on the aerobic biodegradation of tetracycline antibiotics in swine wastewater.
Bai, L; Cao, G; Chen, X; Meng, S; Xue, W; Yang, L; Yuan, C, 2023
)
0.91
"80 mmol/kg) compound group had a significant effect on average well color development (AWCD) and OTC showed a dose-response relationship."( New insights into the effects of antibiotics and copper on microbial community diversity and carbon source utilization.
Dong, Z; Kim, YM; Mao, S; Wang, J; Wang, L; Wen, S; Yan, X; Zhang, W; Zhu, L, 2023
)
0.91
" Also, 1 mM HPO dosage led to 100% antibiotic removal ratios after 10 min of DBD treatment and a TOC removal of 62."( Non-thermal plasma activated peroxide and percarbonate for tetracycline and oxytetracycline degradation: Synergistic performance, degradation pathways, and toxicity evaluation.
Kyere-Yeboah, K; Qiao, XC, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (58)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency7.94330.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency0.39810.004023.8416100.0000AID485290
Chain A, Beta-lactamaseEscherichia coli K-12Potency100.00000.044717.8581100.0000AID485294
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency4.45630.140911.194039.8107AID2451
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency1.41250.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency19.95260.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency11.22020.125919.1169125.8920AID2549
thioredoxin reductaseRattus norvegicus (Norway rat)Potency35.48130.100020.879379.4328AID588453
WRNHomo sapiens (human)Potency19.95260.168331.2583100.0000AID651768
phosphopantetheinyl transferaseBacillus subtilisPotency56.23410.141337.9142100.0000AID1490
USP1 protein, partialHomo sapiens (human)Potency44.66840.031637.5844354.8130AID743255
GLS proteinHomo sapiens (human)Potency7.07950.35487.935539.8107AID624170
Microtubule-associated protein tauHomo sapiens (human)Potency8.76490.180013.557439.8107AID1460; AID1468
AR proteinHomo sapiens (human)Potency48.96620.000221.22318,912.5098AID743036
thioredoxin glutathione reductaseSchistosoma mansoniPotency8.91250.100022.9075100.0000AID485364
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency1.00000.707912.194339.8107AID720542
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency7.94330.00137.762544.6684AID914; AID915
regulator of G-protein signaling 4Homo sapiens (human)Potency79.43280.531815.435837.6858AID504845
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency11.98770.01237.983543.2770AID1645841
pregnane X nuclear receptorHomo sapiens (human)Potency27.30600.005428.02631,258.9301AID1346982
cytochrome P450 2D6Homo sapiens (human)Potency37.90830.00108.379861.1304AID1645840
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency2.81840.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency11.22020.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency61.13060.000723.06741,258.9301AID743122
thyroid stimulating hormone receptorHomo sapiens (human)Potency27.30600.001628.015177.1139AID1259385
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency17.37390.057821.109761.2679AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency100.71500.039147.5451146.8240AID1224845
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency11.22020.036619.637650.1187AID1466; AID2242
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency22.38720.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency79.43280.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency3.98110.006026.168889.1251AID540317
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency47.64090.010039.53711,122.0200AID1469; AID1479
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency50.11870.794321.275750.1187AID624246
importin subunit beta-1 isoform 1Homo sapiens (human)Potency112.20205.804836.130665.1308AID540263
DNA polymerase betaHomo sapiens (human)Potency2.81840.022421.010289.1251AID485314
flap endonuclease 1Homo sapiens (human)Potency11.22020.133725.412989.1251AID588795
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency28.18380.65619.452025.1189AID463254
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency5.32330.168316.404067.0158AID720504
snurportin-1Homo sapiens (human)Potency112.20205.804836.130665.1308AID540263
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency51.52020.000627.21521,122.0200AID743202; AID743219
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency35.48130.425612.059128.1838AID504891
DNA polymerase eta isoform 1Homo sapiens (human)Potency3.98110.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency50.11870.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency1.77830.004611.374133.4983AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency2.81840.031622.3146100.0000AID588579
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency39.81070.00419.962528.1838AID2675
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency28.18380.251215.843239.8107AID504327
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)Potency35.48130.058010.694926.6086AID602310
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency31.62286.309660.2008112.2020AID720709
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency11.22023.548118.039535.4813AID1466
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Potency11.22023.548118.039535.4813AID1466
phosphoglycerate kinaseTrypanosoma brucei brucei TREU927Potency25.11890.07578.474229.0628AID602233
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Valosin-containing proteinHomo sapiens (human)IC50 (µMol)50.00000.11006.018728.0000AID1534; AID1544
microphthalmia-associated transcription factor isoform 9Homo sapiens (human)IC50 (µMol)1.70870.00481.37104.9290AID1259371; AID1259373; AID1259375
eukaryotic translation initiation factor 4 gamma 1 isoform 4Homo sapiens (human)IC50 (µMol)50.00001.150012.620025.6529AID855
eukaryotic translation initiation factor 4E isoform 1Mus musculus (house mouse)IC50 (µMol)50.00001.150012.620025.6529AID855
Serum paraoxonase/arylesterase 1Homo sapiens (human)Ki200.00009.00009.00009.0000AID1803291
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (28)

Processvia Protein(s)Taxonomy
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of plasma lipoprotein oxidationSerum paraoxonase/arylesterase 1Homo sapiens (human)
cholesterol metabolic processSerum paraoxonase/arylesterase 1Homo sapiens (human)
response to toxic substanceSerum paraoxonase/arylesterase 1Homo sapiens (human)
positive regulation of cholesterol effluxSerum paraoxonase/arylesterase 1Homo sapiens (human)
carboxylic acid catabolic processSerum paraoxonase/arylesterase 1Homo sapiens (human)
organophosphate catabolic processSerum paraoxonase/arylesterase 1Homo sapiens (human)
phosphatidylcholine metabolic processSerum paraoxonase/arylesterase 1Homo sapiens (human)
lactone catabolic processSerum paraoxonase/arylesterase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
aryldialkylphosphatase activitySerum paraoxonase/arylesterase 1Homo sapiens (human)
arylesterase activitySerum paraoxonase/arylesterase 1Homo sapiens (human)
calcium ion bindingSerum paraoxonase/arylesterase 1Homo sapiens (human)
phospholipid bindingSerum paraoxonase/arylesterase 1Homo sapiens (human)
protein homodimerization activitySerum paraoxonase/arylesterase 1Homo sapiens (human)
acyl-L-homoserine-lactone lactonohydrolase activitySerum paraoxonase/arylesterase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular regionSerum paraoxonase/arylesterase 1Homo sapiens (human)
extracellular spaceSerum paraoxonase/arylesterase 1Homo sapiens (human)
endoplasmic reticulum membraneSerum paraoxonase/arylesterase 1Homo sapiens (human)
extracellular exosomeSerum paraoxonase/arylesterase 1Homo sapiens (human)
blood microparticleSerum paraoxonase/arylesterase 1Homo sapiens (human)
high-density lipoprotein particleSerum paraoxonase/arylesterase 1Homo sapiens (human)
spherical high-density lipoprotein particleSerum paraoxonase/arylesterase 1Homo sapiens (human)
extracellular spaceSerum paraoxonase/arylesterase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (174)

Assay IDTitleYearJournalArticle
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347158ZIKV-mCherry secondary qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347156DAPI mCherry counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347164384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1241206Inhibition of pre-miR-17 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1241225Binding affinity to 5'-FAM-pre-miR-372 (unknown origin) assessed as change in total free energy by thermodynamic assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1241209Binding affinity to 5'-FAM-pre-miR-372 (unknown origin) after 4 hrs by fluorescence assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID1241215Ratio of Kd for 5'-FAM-pre-miR-372 (unknown origin) in presence of 100-fold excess of 15-mer DNA to Kd for 5'-FAM-pre-miR-372 (unknown origin)2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID1525089Antimicrobial activity against Micrococcus luteus DSM 1790 by serial dilution assay2019Journal of natural products, 05-24, Volume: 82, Issue:5
Sesquiterpenes from an Eastern African Medicinal Mushroom Belonging to the Genus Sanghuangporus.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1832231Antimicrobial activity against Corynebacterium glutamicum ATCC 13032 assessed as reduction in bacterial growth incubated for 48 hrs by microdilution susceptibility test
AID1241207Inhibition of pre-miR-373 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1241208Inhibition of pre-miR-21 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID584115Antibacterial activity against Escherichia coli KAM32 harboring pSP72 by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus.
AID1675236Antimicrobial activity against Micrococcus luteus DSM1790 by serial dilution method2020Journal of natural products, 08-28, Volume: 83, Issue:8
Heimiomycins A-C and Calamenens from the African Basidiomycete
AID396000Antimicrobial activity against Mycoplasma putrefaciens French isolates after 24 hrs by twofold serial dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibilities of Mycoplasma putrefaciens field isolates.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID409949Inhibition of human liver MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID396001Antimicrobial activity against Mycoplasma putrefaciens Jordanian isolates after 24 hrs by twofold serial dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibilities of Mycoplasma putrefaciens field isolates.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1433220Antibacterial activity against Staphylococcus aureus DSM 346 after 24 to 48 hrs by serial dilution method2016Journal of natural products, 06-24, Volume: 79, Issue:6
Pyristriatins A and B: Pyridino-Cyathane Antibiotics from the Basidiomycete Cyathus cf. striatus.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID681050TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.05 uM, Oxytetracycline: 50 uM) in OAT3-expressing S2 cells2002Japanese journal of pharmacology, Jan, Volume: 88, Issue:1
Human organic anion transporters mediate the transport of tetracycline.
AID1525188Antibacterial activity against Staphylococcus aureus Newman by serial dilution method2019Journal of natural products, 05-24, Volume: 82, Issue:5
Kenalactams A-E, Polyene Macrolactams Isolated from Nocardiopsis CG3.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID584116Ratio of MIC for Escherichia coli KAM32 harboring cloned pSP72 lmrS to MIC for Escherichia coli KAM32 harboring pSP722010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1832232Antimicrobial activity against Staphylococcus aureus ATCC 9144 assessed as reduction in bacterial growth incubated for 48 hrs by microdilution susceptibility test
AID1675234Antimicrobial activity against Bacillus subtilis DSM10 by serial dilution method2020Journal of natural products, 08-28, Volume: 83, Issue:8
Heimiomycins A-C and Calamenens from the African Basidiomycete
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1832230Antimicrobial activity against Escherichia coli ATCC 25922 assessed as reduction in bacterial growth incubated for 48 hrs by microdilution susceptibility test
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1566488Inhibition of Dicer mediated biotinylated pre-miRNA-21 (unknown origin) maturation preincubated for 15 mins followed by pre-miRNA-21 addition and measured after 5 hrs by cat-ELCCA2019ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5
Tetracyclines as Inhibitors of Pre-microRNA Maturation: A Disconnection between RNA Binding and Inhibition.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1241203Inhibition of pre-miR-17 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis at 200 uM by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1566490Inhibition of Dicer mediated biotinylated pre-miRNA-21 (unknown origin) maturation at 1 mM measured after 15 mins by cat-ELCCA relative to control2019ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5
Tetracyclines as Inhibitors of Pre-microRNA Maturation: A Disconnection between RNA Binding and Inhibition.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID679404TP_TRANSPORTER: inhibition of PAH uptake (PAH: 5 uM, Oxytetracycline: 500 uM) in OAT1-expressing S2 cells2002Japanese journal of pharmacology, Jan, Volume: 88, Issue:1
Human organic anion transporters mediate the transport of tetracycline.
AID1433218Antibacterial activity against Micrococcus luteus DSM 1790 after 24 to 48 hrs by serial dilution method2016Journal of natural products, 06-24, Volume: 79, Issue:6
Pyristriatins A and B: Pyridino-Cyathane Antibiotics from the Basidiomycete Cyathus cf. striatus.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1241201Inhibition of pre-miR-372 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis at 200 uM by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1887351Antibacterial activity against Bacillus subtilis DSM 10 assessed as inhibition of bacterial growth incubated overnight by serial dilution method
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1349916Antimicrobial activity against Staphylococcus aureus DSM 346 after 16 to 48 hrs by serial dilution method2018Journal of natural products, 02-23, Volume: 81, Issue:2
Cysteine-Derived Pleurotin Congeners from the Nematode-Trapping Basidiomycete Hohenbuehelia grisea.
AID1241214Binding affinity to 5'-FAM-pre-miR-372 (unknown origin) after 4 hrs by fluorescence assay in presence of 100-fold excess of 15-mer DNA2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID680948TP_TRANSPORTER: inhibition of PGF2alpha uptake (PGF2alpha: 0.005 uM, Oxytetracycline: 5 uM) in OAT2-expressing S2 cells2002Japanese journal of pharmacology, Jan, Volume: 88, Issue:1
Human organic anion transporters mediate the transport of tetracycline.
AID1566489Inhibition of biotinylated pre-let-7d microRNA (unknown origin) maturation preincubated for 15 mins followed by Pre-let-7d addition and measured after 5 hrs by cat-ELCCA2019ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5
Tetracyclines as Inhibitors of Pre-microRNA Maturation: A Disconnection between RNA Binding and Inhibition.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1241210Binding affinity to 5'-FAM-pre-miR-17 (unknown origin) after 4 hrs by fluorescence assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1111407Antibacterial activity against Serratia marcescens subsp. marcescens KRICT4 at 1.6 mg/l after 24 hr2010Pest management science, Jun, Volume: 66, Issue:6
Suppression of pine wilt disease by an antibacterial agent, oxolinic acid.
AID584114Antibacterial activity against Escherichia coli KAM32 harboring Staphylococcus aureus cloned pSP72 lmrS by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus.
AID1111406Antibacterial activity against Enterobacter asburiae KRICT3 at 1.6 mg/l after 24 hr2010Pest management science, Jun, Volume: 66, Issue:6
Suppression of pine wilt disease by an antibacterial agent, oxolinic acid.
AID1525190Antibacterial activity against Bacillus subtilis DSM10 by serial dilution method2019Journal of natural products, 05-24, Volume: 82, Issue:5
Kenalactams A-E, Polyene Macrolactams Isolated from Nocardiopsis CG3.
AID1241202Inhibition of pre-miR-373 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis at 200 uM by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1525189Antibacterial activity against Escherichia coli DSM1116 by serial dilution method2019Journal of natural products, 05-24, Volume: 82, Issue:5
Kenalactams A-E, Polyene Macrolactams Isolated from Nocardiopsis CG3.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1241211Binding affinity to 5'-FAM-pre-miR-373 (unknown origin) after 4 hrs by fluorescence assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID1241204Inhibition of pre-miR-21 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis at 200 uM by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID1433216Antibacterial activity against Chromobacterium violaceum DSM 30191 after 24 to 48 hrs by serial dilution method2016Journal of natural products, 06-24, Volume: 79, Issue:6
Pyristriatins A and B: Pyridino-Cyathane Antibiotics from the Basidiomycete Cyathus cf. striatus.
AID1241212Binding affinity to 5'-FAM-pre-miR-372 (unknown origin) after 4 hrs by fluorescence assay in presence of 100-fold excess of Escherichia coli tRNA2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID625277FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1349915Antimicrobial activity against Micrococcus luteus DSM 1790 after 16 to 48 hrs by serial dilution method2018Journal of natural products, 02-23, Volume: 81, Issue:2
Cysteine-Derived Pleurotin Congeners from the Nematode-Trapping Basidiomycete Hohenbuehelia grisea.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID396002Antimicrobial activity against Mycoplasma putrefaciens KS1 after 24 hrs by twofold serial dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibilities of Mycoplasma putrefaciens field isolates.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID680188TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.05 uM, Oxytetracycline: 50 uM) in OAT4-expressing S2 cells2002Japanese journal of pharmacology, Jan, Volume: 88, Issue:1
Human organic anion transporters mediate the transport of tetracycline.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1525091Antimicrobial activity against Staphylococcus aureus DSM 346 by serial dilution assay2019Journal of natural products, 05-24, Volume: 82, Issue:5
Sesquiterpenes from an Eastern African Medicinal Mushroom Belonging to the Genus Sanghuangporus.
AID1241213Ratio of Kd for 5'-FAM-pre-miR-372 (unknown origin) in presence of 100-fold excess of Escherichia coli tRNA to Kd for 5'-FAM-pre-miR-372 (unknown origin)2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID1241205Inhibition of pre-miR-372 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID1404404Antimicrobial activity against Micrococcus luteus DSM 1790 by serial dilution method2018Journal of natural products, 04-27, Volume: 81, Issue:4
Microporenic Acids A-G, Biofilm Inhibitors, and Antimicrobial Agents from the Basidiomycete Microporus Species.
AID1866142Antibacterial activity aginst Bacillus subtilis DSM 10 assessed as inhibition of bacterial growth incubated for overnight by serial dilution method
AID1866146Antibacterial activity against Micrococcus luteus DSM 1790 assessed as inhibition of bacterial growth incubated for overnight by serial dilution method
AID1866153Antibacterial activity against Staphylococcus aureus DSM 346 assessed as inhibition of bacterial growth incubated for overnight by serial dilution method
AID1866145Antibacterial activity against Escherichia coli DSM 1116 assessed as inhibition of bacterial growth incubated for overnight by serial dilution method
AID1866144Antibacterial activity against Chromobacterium violaceum DSM 30191 assessed as inhibition of bacterial growth incubated for overnight by serial dilution method
AID1404405Antimicrobial activity against Staphylococcus aureus DSM 346 by serial dilution method2018Journal of natural products, 04-27, Volume: 81, Issue:4
Microporenic Acids A-G, Biofilm Inhibitors, and Antimicrobial Agents from the Basidiomycete Microporus Species.
AID1404414Antimicrobial activity against Staphylococcus aureus DSM 1104 by serial dilution method2018Journal of natural products, 04-27, Volume: 81, Issue:4
Microporenic Acids A-G, Biofilm Inhibitors, and Antimicrobial Agents from the Basidiomycete Microporus Species.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1803291PON Activity Assay from Article 10.3109/14756366.2012.681653: \\Impacts of some antibiotics on human serum paraoxonase 1 activity.\\2013Journal of enzyme inhibition and medicinal chemistry, Aug, Volume: 28, Issue:4
Impacts of some antibiotics on human serum paraoxonase 1 activity.
AID1265631Antibacterial activity against Streptococcus iniae after 24 hrs by broth microdilution method2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Dimeric Octaketide Spiroketals from the Jellyfish-Derived Fungus Paecilomyces variotii J08NF-1.
AID1265629Antibacterial activity against Vibrio ichthyoenteri after 24 hrs by broth microdilution method2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Dimeric Octaketide Spiroketals from the Jellyfish-Derived Fungus Paecilomyces variotii J08NF-1.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6,153)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904310 (70.05)18.7374
1990's376 (6.11)18.2507
2000's428 (6.96)29.6817
2010's639 (10.39)24.3611
2020's400 (6.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 5.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index5.79 (24.57)
Research Supply Index8.85 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (5.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials267 (3.97%)5.53%
Reviews86 (1.28%)6.00%
Case Studies166 (2.47%)4.05%
Observational2 (0.03%)0.25%
Other6,200 (92.25%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]